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ABSTRACT 
              Liliana Angelica Ponguta 
Epidermal Growth Factor-Meditated Signaling in Recurrent Prostate Cancer 
(Under the direction of Elizabeth M. Wilson, Ph.D) 
 
The androgen receptor (AR) is required for prostate cancer development and 
contributes to tumor progression following remission in response to androgen deprivation 
therapy. Epidermal growth factor (EGF) increases AR transcriptional activity at low 
levels of androgen in the CWR-R1 prostate cancer cell line derived from the castration-
recurrent CWR22 prostate cancer xenograft. Our studies indicated that EGF does not 
regulate TIF2 mRNA levels and that TIF2 is required for AR transactivation induced by 
DHT and EGF in CWR-R1 cells. Real-time RT-PCR was used to determine that hK2 is a 
suitable marker for androgen-regulated gene transcription in CWR-R1 cells and that DHT 
does not up-regulate EGF transcription. Here we report that knockdown of AR decreases 
EGF stimulation of prostate cancer cell growth and demonstrate a mechanistic link 
between EGF and AR signaling. The EGF induced increase in AR transcriptional activity 
is dependent on phosphorylation at MAP kinase consensus site Ser-515 in the AR NH2-
terminal region and at protein kinase C consensus site Ser-578 in the AR DNA binding 
domain. Phosphorylation at these sites alters the nuclear-cytoplasmic shuttling of AR and 
AR interaction with the Ku-70/80 regulatory subunits of DNA-dependent protein kinase. 
Abolishing AR Ser-578 phosphorylation by introducing an S578A mutation eliminates 
the AR transcriptional response to EGF, increases both AR binding of Ku-70/80 and 
 iv 
nuclear retention of AR in association with hyperphosphorylation of AR Ser-515. AR-
S578A did not transactivate the MMTV-Luc reporter and we show the negative 
regulatory element-1 in the long terminal repeat of MMTV mediates AR-induced 
transcription of that promoter.  The results support a model in which AR transcriptional 
activity increases castration-recurrent prostate cancer cell growth in response to EGF by 
site-specific serine phosphorylation that regulates nuclear-cytoplasmic shuttling through 
interactions with the Ku-70/80 regulatory complex. 
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INTRODUCTION 
 
PROSTATE CANCER: EPIDEMIOLOGY, NATURAL HISTORY AND CURRENT TREATMENTS 
The prostate gland is the most common site of neoplastic disorders in men with 
50% developing benign prostate hyperplasia (BPH) by the age of 50. At 80 years of age 
BPH is present in approximately 90% of men and 23% will develop prostate cancer  (1). 
According to the American Cancer Society in 2008 about 186,320 new cases of prostate 
cancer will be diagnosed in the United States and 28,660 men will die from it, accounting 
for about 9% of cancer-related deaths.  The incidence of prostate cancer extends also to 
other Western countries where it is the most prevalent male malignancy and ranks among 
the top three causes of death due to cancer (2). The pathogenesis of BPH and prostate 
cancer is poorly understood (3).  
Epidemiologic studies on prostate cancer risk factors point to endocrine function, 
growth factors, diet, occupational exposures and genetic factors as possible etiologies of 
the disease (4). Recent cohort studies have identified multiple loci with moderate effects 
associated with susceptibility to prostate cancer. One of the largest, most recent genome- 
wide association studies identified copine III (CPNE3) of the calcium-dependent 
phospholipid-binding proteins, interleukin-16 (IL16) and cadherin 13 (CDH13) as 
possible prostate cancer susceptibility genes (5). Polymorphisms of breast cancer genes 
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1/2 (BRAC 1/2) and CHK2 checkpoint homolog (CHEK2), involved in DNA repair, have 
also been recently associated with prostate cancer development (6,7). Supporting 
evidence is required to determine the role of identified genetic polymorphisms and their 
potential interaction with environmental factors in the pathogenesis of prostate cancer.  
Despite the number of candidate susceptibility genes involving multiple cellular 
pathways, the natural history of prostate cancer has been consistently linked to androgen 
signaling and the androgen receptor (AR), a member of the steroid superfamily of 
transcription factors. Androgens support the development and survival of normal and 
malignant prostate tissue by binding and transcriptionally activating AR. Polymorphisms 
of several genes directly involved in androgen synthesis, such as CYP11A1, 
CYP17A1/A2, and CYP19A1 from the cytochrome P450 family, are under study as 
biomarkers for prostate cancer susceptibility (8-11). Further, reports point to 
polymorphisms in AR (12-15) and AR coactivators, such as amplified in breast cancer-1 
(AIB1) and steroid receptor coactivator 3 (SRC-3) (16), as increased risk factors of 
prostate cancer development.  
The normal prostate is comprised of mature secretory luminal, prostatic basal, and 
neuroendocrine cells.  The luminal or glandular cells constitute the exocrine compartment 
of the prostate and are terminally differentiated. Glandular cells express high levels of 
AR and are dependent on androgen for survival (17). Basal cells rest on the basement 
membrane of the prostate, are relatively undifferentiated and lack secretory activity. 
Unlike glandular cells, stromal cells express low levels of AR and stromal-epithelial cell 
interactions that modulate AR-coregulator recruitment and AR function seem altered in 
the stromal cell microenvironment of prostate cancer (18). Thus, although the great 
majority of cancers originate from gland cell disruption of androgen-regulated pathways, 
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both stromal and epithelial cell compartments may affect the development and 
progression of prostate cancer. 
Neuroendocrine cells reside among the secretory epithelium in the normal 
prostate gland, are terminally differentiated and androgen-insensitive (19). Expression of 
VEGF leading to angiogenesis has been linked to oncogenic activity of neuroendocrine 
cells in the prostate (20). Transformed epithelial cells actively influence stromal cells, 
including inflammatory cells, vascular endothelial cells, and fibroblasts, to generate a 
microenvironment that fosters carcinogenesis (18) resulting in complex paracrine 
regulatory mechanisms during cancer development.  
During the process of malignant transformation, cells gradually progress towards 
the malignant phenotype. Prostatic intraepithelial neoplasia (PIN), defined as a condition 
of neoplastic growth of epithelial cells with preexisting benign acini or ducts, is widely 
accepted as a precursor to prostate cancer (21). Studies suggest that high grade PIN 
represents an intermediate stage between pathological and phenotypical benign 
epithelium and the invasive malignant carcinoma (22-24). High grade PIN diagnosis is of 
clinical significance as it identifies patients at risk of malignancy and the development of 
concurrent carcinoma.  
Initial evaluation of the extent of patient longevity involves clinical variables that 
correlate with the extent of disease. The probability of cure depends on the Gleason score, 
prostate-specific antigen (PSA) level and clinical stage (25). PSA is a serine protease 
believed to liquefy the seminal fluid (26). Prostate cancer is associated with increased 
release of PSA into the circulation, increasing the level in blood by up to 100,000-fold 
(27). PSA testing has come into widespread use as a prostate cancer marker, both for 
initial diagnosis and monitoring response to treatment. Use of PSA has also aided in the 
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prediction of prostate cancer risk and treatment outcome (28). Another prostate cancer 
marker under investigation is human kallikrein 2 (hK2) that, like PSA, is androgen 
regulated, released into seminal fluid, and increased in serum of patients with prostate 
cancer. Several studies have shown that measuring hK2 aids in predicting prostate cancer 
stage, grade and volume and progression to castration-recurrent cancer (29,30). Current 
research is aimed at establishing and developing methods to improve on the conventional 
PSA test to significantly reduce prostate cancer mortality.  
Surgical management of localized or non-metastatic prostate cancer includes 
radical prostatectomy and cryotherapy (controlled freezing) of the prostate in order to 
destroy cancerous cells. Radiotherapy or small pellet radioactive implants 
(brachytherapy) is also used in patients with early stage disease. A number of novel 
agents are being explored to manage patients with advanced prostate cancer, both alone 
and especially in combination. Anti-angiogenic agents, small molecule inhibitors, and 
nucleotide-based targeted therapies are aimed at reducing prostate cancer mortality. 
Markers for tumor angiogenesis, such as microvessel density, have been reported to be 
greater in tumors from men with metastatic prostate cancer than in those with localized 
disease (31). Humanized monoclonal antibody that neutralizes vascular endothelial 
growth factor (VEGF) activity in combination with docetaxel, prednisone, and 
thalidomide has resulted in a high durable 86% response in lowering PSA levels. Small 
molecule inhibitors that specifically block cell signaling involved in growth and 
apoptosis are currently under investigation. For instance, Endothelin-A (ET-A) receptor 
activation by endothelin-1 (ET-1) contributes to tumor growth and progression in prostate 
cancer (32). ETA-1 receptor antagonist delays median time to PSA progression and 
prolongs median time of progression in castration-recurrent prostate cancer patients (33). 
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Antisense oligonucleotides are currently being explored to target genes involved in 
cancer progression (34). Antisense oligonucleotides toward protein kinase C (PKC), 
insulin growth factor binding protein 2, protein kinase A and the B-cell 
leukemia/lymphoma 2 genes are some of the targeting agents that have been studiend in 
clinical trials (35). Although antisense oligonucleotide chemistry holds potential clinical 
advantages, challenges remain to optimize tissue exposure and cellular uptake and to 
demonstrate the underlying mechanism and anti-tumor activity.  
Since androgen activation of AR regulates prostate growth, drug treatment 
modalities are also largely targeted to blocking AR-mediated gene transcription. 
Circulating testosterone levels can be reduced by removing the testes (bilateral 
orchiectomy) or by chemical castration. A second treatment option is the interference 
with adrenal hormones in addition to testicular testosterone (combined androgen 
blockade). Greater understanding of the etiology, pathogenesis and molecular 
mechanisms of prostate cancer development and AR function are required for the 
development of more effective therapies to reduce prostate cancer mortality.  
THE ANDROGEN RECEPTOR AND ANDROGEN RECEPTOR COACTIVATORS 
Androgen action in target cells is mediated by the AR which exhibits a prototypic 
multidomain structure, containing a N-terminal activation domain, a C-terminal ligand-
binding domain, and a centrally located DNA-binding region with two zinc finger motifs 
(36,37).  The AR gene is located on the X chromosome at Xq11-12 (38). Androgen-
induced AR transcriptional activity depends on activation function 1 in the disordered 
NH2-terminal region (37) and activation function 2 (AF2), a highly ordered hydrophobic 
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surface in the ligand binding domain (LBD) that requires androgen binding for its 
structural integrity (39). AR AF2 binds a number of LXXLL-related motifs such as the 
AR NH2-terminal FXXLF motif 23FQNLF27 in an androgen-dependent and specific 
manner (40-42). AR FXXLF motif binding to AF2 is the basis for the AR NH2- and 
carboxyl-terminal (N/C) interaction that contributes to AR dimerization (43,44) and is 
critical for AR regulation of androgen-dependent genes (45) (Figure 1.1).  
AF2 in the ligand binding domain functions as a binding site for SRC/p160 
coactivator LXXLL motifs and for the FXXLF motif present in the AR-NH2 terminus and 
AR coregulators (40,46,47).  Cell- and tissue-specific coactivators influence the 
contribution of AF2 to AR transcriptional activity. For instance, AR AF2 activity in 
prostate cancer has been linked to higher levels of SRC/p160 coactivators that compete 
for the AR N/C interaction and increase AR transcriptional activity through AF2 (48,49). 
Interestingly, transcriptional intermediary factor 2 (TIF2) is highly expressed in the 
majority of advanced castration-recurrent prostate cancers (49). Coactivators can enhance 
transcription of AR dependent genes. Gregory et al. reported that in the CWR22 
xenograft, AR associated protein ARA70 is regulated by androgens and that its levels 
increase during prostate cancer recurrence (50). Bai et al. have recently shown that the 
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AR coregulator melanoma antigen gene protein-11 (MAGE-11) of the MAGEA gene 
family binds the AR FXXLF motif to expose AF2 and increase coactivator recruitment.  
MAGE-11 is expressed in androgen-dependent tissues and in prostate cancer cell lines 
(46). Thus, coactivators have an important role in AR action contributing  to prostate 
tumor development and progression. Overexpression of coactivators facilitates AR 
transactivation particularly at low levels of circulating androgen (51,52).  
In reporter gene assays, androgen binding results in AR nuclear translocation and 
up-regulation of androgen responsive reporter genes through its interaction with androgen 
response elements (53).  The major male sex steroids, testosterone (T) and 
dihydrotestosterone (DHT), initiate prostate gland growth and development. Testosterone 
is produced mainly by testicular Leydig cells and is converted by type II 5α-reductase in 
the prostate to DHT. Normal levels of T without conversion to DHT fail to stimulate 
complete male genital development of the human fetus as evidenced by the 5 -reductase 
syndrome caused by a genetic defect in the enzyme that converts T to DHT (54). 
Although T and DHT equilibrium binding affinities are similar (55), a 10-fold higher 
concentration of T is required to achieve the AR mediated transcriptional effects of DHT 
(56). Ligand-specific effects of T and DHT result from different physiological potencies, 
where the weaker activity of T, a more polarized steroid than DHT, results in an inability 
to fully stabilize the AF2 binding surface for AR FXXLF and SRC/p160 coactivator 
LXXLL motif binding (52). Inhibition of 5α-reductase isoenzymes to decrease DHT has 
demonstrated benefits in the primary prevention of prostate cancer and potential in 
limiting disease progression in men with diagnosed disease (57). AR and coregulators 
bind to specific androgen response elements in the upstream promoter of target genes 
leading to transcriptional activation and modulation of RNA polymerase II (18,58). 
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Androgen regulation gene expression is controlled by a complex transcriptional 
machinery involving multiple regulatory signals and proteins. Understanding the 
underlying molecular mechanisms of AR function is critical to the development of 
effective prostate cancer treatments.  
CASTRATION-RECURRENT PROSTATE CANCER 
AR plays a key role in the development and maintenance of normal prostate and 
in prostate cancer progression. Alterations in AR itself, as well as interactions with 
growth factors, cofactors, chromatin, post-transcriptional modification mechanisms and 
degradation patterns, can alter AR function providing a selective growth advantage for 
cancer cells (59). Studies suggest amplifications of the AR gene make prostate cancer 
tumors hypersensitive to low levels of androgen. Studies have demonstrated mutations in 
AR result in promiscuity of the response to ligands and antagonists. Other groups have 
reported alterations in kinase signaling lead to an outlaw AR that is responsive to growth 
factor- and kinase-mediated signaling. Studies also indicate paracrine signals from the 
prostatic stroma result in AR transactivation in the presence of low levels of androgen 
(60) (Figure 1.2). The majority of men with non-organ confined prostate cancer initially 
experience regression in response to therapy but virtually all patients relapse and no 
longer respond to conventional anti-neoplastic therapy (61).  
AR is expressed in the majority of castration-recurrent prostate cancers (62) and 
activation of AR contributes to malignant growth despite androgen deprivation. 
Visakorpi et al. reported amplification of the AR gene in 30% of the castration-recurrent 
tumors compared to the specimens taken from the same patients prior to androgen 
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ablation therapy (63). These studies have been verified at the genomic, RNA and protein 
levels in castration-recurrent tumors (63-65).  
Heightened sensitivity of AR to androgens has been proposed as another 
mechanism by which prostate cancer cells proliferate in an androgen-reduced 
environment. Studies by our group showed that the concentration of DHT required for 
growth stimulation of hormone refractory prostate cancer is four orders of magnitude 
lower than that required by androgen dependent cells and that, in the castration-recurrent 
prostate cancer cell line, CWR-R1 (derived from the CWR22 human prostate cancer 
xenograft) the AR is highly expressed, stable and localized to the nucleus (66). The 
human prostate cancer xenograft CWR22 propagated in nude mice maintains 
characteristics of human prostate cancer, including an initial dependence on androgen for 
growth followed by recurrence several months after castration (67,68). CWR22 tumor 
cells harbor a functional, mutated AR (H874Y) that displays broadened ligand specificity 
(69).  
Prostate cancer cells may also evade androgen deprivation therapy through 
increased AR activation through binding of adrenal androgens and estrogens (69). Single 
amino acid point mutations, usually found in the ligand binding domain of AR, can 
decrease specificity of binding and increase AR transactivation of AR-regulated genes 
even in a testicular androgen depleted environment. The frequency of AR mutations 
increases after androgen ablation therapy and some suggest this may be due to a natural 
selection of these cells or environmentally directed mutations (70). Veldsholte et al. 
reported that a mutation in the AR ligand binding domain in LNCaP prostate cancer cells 
results in AR activation by non-androgen ligands, such as progesterone, estradiol, 
cyproterone, acetate, flutamide and nilutamide (65). Adrenal steroids 
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increasetransactivation of AR mutants as shown by Culig et al (71) and others (69,72-74). 
However, the low frequency of AR mutations cannot account for most instances or 
recurrence of prostate cancer during androgen deprivation therapy. The CWR22 human 
prostate xenograft contains an AR mutation at codon 874 (histidine replaced by tyrosine) 
which increases activation by adrenal androgens and hydroxyflutamide (69).  
There are alternative mechanisms that may indirectly involve AR resulting in 
transactivation, such as coactivator binding or growth factor signaling. AR localizes in 
nuclei of prostate cancer cells despite low levels of circulating androgen and appears to 
mediate castration-recurrent growth after androgen deprivation (50). This could be 
explained by the presence of sufficient testosterone or DHT to activate AR in the 
microenvironment of castration-recurrent prostate cancer tissue (50,75,76). On the other 
hand, cell culture studies suggest that AR transcriptional activity involves growth factor 
signaling under conditions of androgen deprivation. Growth-factor activated pathways 
such as IGF-1, KGF and EGF can activate the AR and can induce AR target genes in the 
absence of androgen (77). Interleukin-6 (IL-6) is elevated in sera and tissue of patients 
with prostate cancer and is able to activate AR in a ligand-independent manner (78).  
Studies by our group have shown that, in the presence of low levels of androgen, 
EGF increases AR transactivation through the phosphorylation of TIF2 (79) (Figure 1.2). 
We have also shown that heregulin (HRG) signaling through HER2 and HER3 (members 
of the EGFR1-4 tyrosine kinases) increases AR transactivation and alters growth in 
CWR-R1 cells (80) (Figure 1.3). Other studies have shown the involvement of receptor 
tyrosine kinase signaling by demonstrating that overexpression of Her2/neu can activate 
AR dependent genes in the absence of androgen  but not in the absence of AR (79,80). 
Understanding the pathways of AR activation in response to mitogens as well as the role 
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of AR in evasion of hormone deprivation therapy is of critical importance given the 
substantial data that implicates its function during recurrence. Histone modifications 
influence binding of AR to cognate DNA sequences and can modulate the transcriptional 
activation of androgen-regulated genes. For instance, coactivator associated arginine 
methyl transferase (CARM1) mediates histone H3 methylation at androgen-regulated 
enhancer elements in response to androgenic stimuli (81). Interestingly, bicalutamide, an 
AR antagonist, was reported to facilitate histone methylation (82,83), suggesting that 
standard antiandrogen treatment may also work as a chromatin structure modifier.  
Strategies directed to inhibit AR signaling after initial androgen ablation are 
aimed at decreasing the level of ligand by inhibiting adrenal androgen synthesis 
(ketoconazole) or inhibiting 17,20 lyase (abiraterone) and 5α-reductase (finasteride), 
important enzymes in the metabolism of androgens (84). Other agents for inhibiting AR 
function are antiandrogens based on AR crystal structures, antisense AR, or Hsp90 
chaperone inhibitors that induce protein degradation. Histone deacetylase inhibitors and 
drugs targeting coregulatory molecules are also under evaluation as AR signaling 
blocking agents (84). Development of future therapy for prostate cancer will be aided by 
improving knowledge of AR action in prostate cancer. 
ANDROGEN RECEPTOR PHOSPHORYLATION 
Steroid receptors act as sensors for growth-factor signaling. AR acts as a 
transcription factor that integrates multiple extracellular signals (85). However, there is 
little consensus on the functional role of AR phosphorylation and its influence on 
transactivation, whether the effects are directly on AR or indirect through modifications 
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of associated coactivators. Interestingly, Akt  was reported to suppress androgen-induced 
apoptosis by phosphorylating and inhibiting AR, suggesting AR has dual roles in the 
promotion of cell growth and apoptosis in response to posttranscriptional modifications 
(86).  
Previous studies by our group and others have identified phosphorylation sites in 
AR (87,88). Recently, seven major AR phosphorylation sites were mapped, 
demonstrating constitutive phosphorylation of Ser-94, phosphorylation in response to 
androgen of serines 16, 81, 256, 308, 424 and 650, and phosphorylation in response to 
EGF, PMA and forsolkin of Ser-650 (85). Differential regulation of AR serine 
phosphorylation may explain the differences in AR activity induced by either androgens 
or growth factors. AR Ser-213 is phosphorylated in vivo specifically in non-proliferating 
epithelial cells (89). This suggests regulatory roles for AR phosphorylation in prostate 
cell growth and differentiation. Consensus phosphorylation sites in AR suggest that it can 
be a substrate for the DNA-dependent protein kinase, protein kinase A, protein kinase C, 
mitogen-activated kinase, and casein kinase II (90). The PKC isozyme family is 
comprised of at least 10 related kinases, key regulators of cellular responses that include 
proliferation, differentiation, transformation, survival, and apoptosis. These kinases are 
classified based on their structural and biochemical properties and each PKC has unique 
modes of regulation that involve phosphorylation, protein-protein interactions, and 
intracellular targeting—mechanisms that confer isozyme specificity in substrate 
phosphorylation (91-93) and some are downstreatm effectors of growth factor-induced 
stimuli. EGF increases AR activity in prostate cancer cell lines, suggesting that AR 
phosphorylation may result from growth factor signaling. Despite the large body of data 
implicating mitogen-activated protein kinase (MAPK) and phosphatidylinositol-3-kinase 
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(PI3K) signaling on AR function, it remains to be established whether growth factor 
signaling directly phosphorylates AR. An in vitro study showed that mutating AR Ser-
515 resulted in an unphosphrylated form of AR Ser-650 suggesting inter-site regulation 
of AR phosphorylation (94).  
Tyrosine phosphorylation has also been implicated in AR transactivation. Prostate 
cancer growth was linked to src and activated Cdc42-associated tyrosine kinase (Ack1) 
mediated phosphorylation of AR tyrosine residues 267 and 363 in the AR NH2-terminal 
region (40, 41). Further, the AR-Y534F mutation diminished Src-induced tyrosine 
phosphorylation, suggesting AR-Y534 is a site in mitogen-induced AR phosphorylation 
in prostate cancer cells (95).  
Establishing the biological relevance of AR phosphorylation, including the effects 
on stability, nuclear localization, and expression levels is critical to our understanding of 
the convergence between androgen and receptor tyrosine kinase (RTK) activated 
pathways. Discerning the interaction between MAP kinase, PI3K signaling pathways and 
AR, may open possibilities for improved therapy.  
GROWTH FACTOR SIGNALING IN ANDROGEN RECEPTOR TRANSCRIPTIONAL ACTIVITY 
The epidermal growth factor (HER) family of RTKs, through binding of 
extracellular growth factor ligands mediate intracellular signal transduction. The HER 
family in humans is comprised of four members: ErbB1-EGFR, ErbB2 (HER2/neu), 
ErbB3/HER3, and ErbB4/HER4, which are activated upon ligand-induced receptor 
homo- and/or heterodimerization, suggesting that the HER receptor family has evolved a 
complex system of signal diversity. Activation of the EGF signaling network in response 
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to receptor tyrosine kinase activation results in a variety of responses, such as cell 
proliferation, differentiation, cell motility and survival (96). A wealth of clinical data has 
demonstrated that EGFR and HER2 contribute to the development of human cancer (97). 
However, it remains unclear how HER2/neu affects prostate cancer progression and AR 
function. Interestingly, EGF, the natural ligand for EGFR, induces AR transcriptional 
activity in the absence (98) and presence (99) of androgen. The implications of these 
observations for prostate cancer progression also remain ill-defined. We (preliminary 
results) observed a 2-3 fold increase in mouse mammary tumor virus (MMTV) reporter 
activity in response to EGF alone in CWR-R1 cells. The significance and mechanism of 
the EGF-mediated increase in transactivation and possible post-transcriptional 
modifications remain to be fully characterized and understood. Castration-recurrent 
CWR22 prostate xenograft tumors express high levels of EGF-related ligands compared 
with the androgen dependent tumor (76). We have shown that in CWR-R1 cells, 
androgen does not increase the expression of EGF (preliminary results), suggesting that 
there are paracrine or other signaling mechanisms independent of DHT that trigger 
growth factor cascades in the cell. Studies have not only implicated the EGFR axis in 
cancer progression and recurrence but the HER3 and HER4 axis as well. HER2/HER3 or 
HER2/HER4 heterodimerization occurs in response to HRG binding (80). We have 
demonstrated that HRG signaling through the HER2 and HER3 axis increases AR 
transactivation and the growth in CWR-R1 cells. Low level HER2/HER3, activation 
perhaps by an autocrine pathway, contributes to the proliferative signals during cancer 
recurrence (80).  Studies using the dual EGFR/HER2 inhibitor PKI-166 suggest that 
signaling through the HER2/HER3 heterodimer stabilizes AR protein levels and 
optimizes binding of AR to promoter/enhancer regions of androgen-regulated genes 
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(100). Taken together, expression and signaling activity of growth factor receptors and 
their ligands in castration-recurrent prostate cancer suggest cross-talk between AR and 
loops which drives growth in the hormone deprived patient.  
Residual androgens have been shown to be present in human prostate cancer 
tissue even after castration and, interestingly, it has been proposed that castration-
recurrent prostate cancer cells, may synthesize testosterone from adrenal androgens or 
cholesterol (76). Regardless of the persisting presence of androgen in the 
microenviroment of cells, the influence of growth factor signaling on AR is important to 
understand the biology of prostate cancer in the androgen-deprived patient.  
Growth factor stimulation of receptor tyrosine kinases activates different cell-
signaling cascades that result in cell survival and proliferation. Nuclear hormone receptor 
function modulation implicated multiple kinase pathways (101). For instance, Kato et al. 
demonstrated that regulation of estrogen receptor α (ERα) by MAP kinase occurs directly 
through ERα phosphorylation (102). Others have shown that activation of the ERα can 
occur by p160 nuclear receptor coactivator binding (103,104). The serine/threonine 
kinase Raf-1 is a major regulator of the MAPK pathway and has been associated with the 
progression of prostate cancer to the more advanced disease (105). There is evidence to 
suggest that Raf/MEK/ERK signaling plays a critical role in the modulation of AR 
activity in response to Ras. For instance, MAP kinase activity in prostate cancer 
correlates with progression to advanced disease (106).  MAP kinase signaling and 
overexpressed HER2 induce ligand-mediated increases in AR transactivation (107). Our 
observations linking EGF, MAP kinase, TIF2 and AR, suggest that kinase activity is 
important during recurrence in the CWR22 model. Bakin et al. (106) demonstrated that in 
prostate cancer cells expressing a constitutively active Ras, which up-regulates MAPK 
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activity, there is an increase in sensitivity to stimulation with low doses of androgen. 
Interestingly, other studies showed that increased pAkt (a second effector of Ras), alone 
or together with decreased pERK, is an important predictor of failure to reduce serum 
PSA levels (108). Thus, AR transactivation through the MAP kinase phosphorylation 
signal cascade may provide an alternative explanation to AR activation in ligand-depleted 
environments, although the mechanisms of kinase signaling modulation remain unclear. 
Additionally, protein kinase Akt is implicated in prostate cancer progression in an AR-
dependent and AR-independent manner. Wen et al. showed that activation of the AR by 
HER2 is due to Akt phosphorylation at serine 213 and 791. HER-2/neu activated Akt 
(protein kinase B) to promotes prostate cancer cell survival and growth in the absence of 
androgen (109), implicating Akt signaling in prostate cancer recurrence. Further, prostate 
cancer invasion and metastasis are regulated partly by androgens through the PI3K 
pathway. Matrix metalloproteinase 2, which is highly expressed in aggressive prostate 
cancers and is involved in extracellular matrix degradation, is up-regulated by androgen 
through the PI3K pathway (106). Further, studies show that constitutively active Akt is 
involved in androgen-initiated up-regulation of hypoxia-inducible factor-1, which in turn 
stimulates vascular endothelial growth factor production, implicating PI3K signaling in 
the acquisition of aggressive metastatic potential of cancer cells (110). Activation of the 
PI3K pathway is implicated in antiapoptotic events by insulin-like growth factor protein I 
(IGFBP-1) through Akt (70). Activation of PI3K is counteracted by the phosphatase and 
tensin homolog PTEN. In prostate cancer, decreased PTEN activation is associated with 
high Gleason grade (111), and in LNCaP cells, loss of PTEN expression shows 
constitutively active Akt (112). Interestingly, PTEN is frequently mutated with loss of 
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function in advanced prostate cancers (113). Taken together, these data indicate that the 
Raf/MEK/ERK1/2 and PI3K-PDK-Akt pathways influence cancer progression.  
ANDROGEN RECEPTOR DNA BINDING DOMAIN  
Nuclear receptors are divided into four major subfamilies based on the DNA 
sequences they recognize (36,114). DNA binding domains of nuclear receptors contain 
three α-helices arranged in two zinc finger motifs (115). The first α-helix of the amino 
terminal zinc finger contains a 5 amino acid peptide residue stretch forming the proximal 
box (P-box) which makes base-specific contacts with the nucleotide bases in the DNA 
major groove and are responsible for the sequence-specific DNA recognition (116).  AR 
is member of the class I receptor subgroup which includes the glucocorticoid (GR), 
progesterone (PR), and mineralocorticoid  receptors (MR) all of which have a GSCKV P-
box motif sequence that specifically recognizes the hexamer DNA motif 5’-TGTTCT-3’ 
(114,117,118). Aminoacid residues that determine optimal spacing of three base pairs 
between core recognition motifs were localized to the region between the first and second 
cysteines of the second zinc finger module, called distal or dimerization box (D-box) 
based on the relative position and its role in receptor dimerization interface (116).  
 Base-specific interactions of P-box residues are stabilized by a number of 
nonspecific interactions of the amino- and carboxy-terminal part of the DBD and the 
DNA phosphate backbone (119). Class I NRs recognize similar DNA binding motifs and 
yet cellular responses are specific to androgen, glucocorticoid, mineralocorticoid, and 
progesterone stimulation. Some of the mechanisms postulated to explain differential 
receptor expression include hormone metabolism in hormone responsive tissue cells 
(120), differential cooperativity with transcription factor binding to hormone receptor-
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specific regulatory DNA regions (121,122), and differential expression and/or receptor-
specific interaction with co-regulators (123).  AR binding to androgen response elements 
may lead to changes in the conformation of AR-NTD and intra-domain communication 
between the NTD and DBD of AR, resulting in changes in protein conformation and 
protein-DNA interactions (124). Multiple mechanisms likely establish specificity for AR-
dependent DNA binding and target gene regulation.  
Mutations in the P- and D-boxes of AR have been identified in the androgen 
insensitivity syndrome (AIS). One of these mutations at Ser-578 in the P-box resulted in 
partial responsiveness to androgen treatment. These cases indicate that the P- and D-
boxes sites influence AR function during normal development and in hormone-related 
diseases. 
Studies on PR suggest there is both basal and hormone induced phosphorylation 
and that hormone-induced phosphorylation of PR involves DNA-independent and DNA-
dependent stages (125). A model of a three stage PR phosphorylation suggests 
phosphorylation occurs in a progressive cascade directly or by facilitating appropriate 
protein-protein contacts. Further investigation is required to determine the role of 
hormone-induced AR phosphorylation on DNA binding and the regulation of gene 
transcription.   
The role of nuclear receptor DNA binding domains goes beyond DNA sequence 
recognition and binding. Nuclear export shuttling is regulated by signals within nuclear 
receptor DNA binding domains and nuclear localization signals. The GFP-AR-
F582,583A double mutant resulted in AR nuclear arrest suggesting that residues of AR 
DBD influence receptor recycling (126). The mechanism by which AR DBD residues 
regulate nuclear exit are yet to be fully understood.  
 22 
KU-70/80-MEDIATED NUCLEAR HORMONE RECEPTOR MODULATION 
The DNA-dependent protein kinase (DNA-PK) has been described as a 
serine/threonine protein kinase that is activated upon association with DNA. DNA-PK is 
composed of a large catalytic subunit (DNA-PKcs) with  a catalytic domain in the PI3K 
family (127), and a regulatory factor comprised of two tightly associated subunits of ~70 
and 83 kD, referred to as Ku70 and Ku80, respectively (128). DNA-PK assists in 
repairing double-strand DNA breaks. The Ku-70/80 heterodimer is involved in later 
stages of the DNA damage response, particularly on non-homologous end-joining 
(129,130). The Ku70/80 heterodimer binds to the free DNA ends of a double strand break 
and recruits DNA-PKcs. Formation of the DNA-PK trimeric complex results in the 
recruitment and phosphorylation of multiple factors involved in the DNA repair and 
ligation (131). A second major role of DNA-PK involves regulation of V(D)J 
recombination as mutations of DNA-PKcs cause x-ray sensitive and V(D)J 
recombination-defective cells (132).  
Activation of DNA-PK involves interactions with DNA and other proteins. 
Recruitment of DNA-PKcs to Ku facilitates the interaction of DNA-PKcs with DNA, 
releasing its catalytic subunit through conformational changes (128). While DNA alone 
can activate DNA-PKcs in the absence of Ku (133), protein–protein interactions may also 
regulate DNA-PK activity. DNA-bound C1D, a human DNA binding protein, can activate 
DNA-PK in a DNA end-independent manner, by altering the structure of the DNA 
double helix (134). Together, the data suggest there are multiple mechanisms of DNA-PK 
activation which may or may not involve canonical double strand DNA break stimuli.  
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The DNA-PK has been implicated in a number of regulatory processes in 
mammalian systems, such as transcriptional regulation. Ku-70/80 is localized to the 
promoter of androgen-dependent PSA gene, as shown by chromatin 
immunoprecipitation. A report suggest Ku-70/80 act as AR transcriptional coactivators in 
reporter assays as siRNA-induced knockdown of Ku-70/80 caused a modest reduction in 
androgen-dependent  PSA transcriptional activation (135). However, a second report 
demonstrated increased AR-dependent transcription of several androgen-regulated genes 
in response to chemical inhibition of DNA-PK catalytic activity (136). There is little 
consensus on the role and mechanisms of DNA-PK-mediated regulation on AR activity. 
DNA-PK has been shown to interact with and/or phosphorylate a number of transcription 
factors including EGFR (137), transcription factor IID (TFIID) (138), Oct-1 (139), PR 
(140) and GR (141,142). Early studies on PR phosphorylation using HeLa nuclear 
extracts suggested PR phosphorylation by DNA-PK in response to addition of DNA 
harboring a progesterone-response element, suggesting that at least one mechanism of 
transcriptional regulation by DNA-PK is through phosphorylation of nuclear hormone 
receptors (143). DNA-PK phosphorylates target proteins preferentially, although not 
exclusively, at the consensus Ser/Thr-Gln (144), however there is no evidence to date of 
DNA-PK phosphorylation of AR in vivo.  
SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRAL VECTOR-MEDIATED INHIBITION 
OF PROTEIN EXPRESSION  
The emergence of RNA interference has enabled the selective suppression of gene 
expression in mammalian cells. Small inhibiting RNAs (siRNAs) trigger specific 
catalytic degradation of complementary mRNAs through the formation of multicatalytic 
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complexes that minimize cytotoxicity associated with long antisense RNAs (145,146). 
Long-term targeted gene suppression through siRNA can be attained in mammalian cells 
using RNA polymerase III promoter-driven hairpin siRNA-producing vector-based 
cassettes. The adeno-associated viral vector delivery system (AAV) has been widely used 
for transgene delivery in mammalian cells. Self-complementatry AAV (scAAV) is a 
derivative of the conventional recombinant AAV which was recently developed as an 
enhanced-efficiency gene delivery vector (147).  
Conventional single-stranded recombinant AAV (rAAV) requires second strand 
synthesis before genes can be expressed. scAAV bypasses this rate limiting step by 
delivering a duplex genome. This was achieved by deleting a minor portion (28 of 145 
bases) of one of the terminal repeats (TR) eliminating it as a replication origin yet 
forming a wild-type AAV TR hairpin structure (148). Rolling hairpin replication from the 
remaining wild-type terminal repeat creates single stranded, dimeric inverted repeat 
genomes, with the altered terminal repeat sequence situated in the middle of the molecule 
and a wild-type TR at each end (149). This unique structure allows for intramolecular 
base pairing to generate the double stranded DNA template for gene expression in the 
absence of DNA synthesis in the target cell. To date, no scAAV driving expression of 
ARsiRNA have been published. Vectors that provide high and potent transduction 
efficiency to inhibit AR protein are valuable tools for the study of AR in prostate cancer 
recurrence.  
DISSERTATION RESEARCH OBJECTIVES 
AR and mitogen signaling are increased during prostate cancer recurrence. The 
relative lack of consensus on the functional effects of AR phosphorylation leave 
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unanswered the question of the significance of growth factors during disease progression 
and the mechanisms by which, during androgen deprivation, kinases regulate AR 
function. The objectives of this dissertation research were to develop a tool for the 
inhibition of AR in prostate cancer cells in order to determine the role of AR in 
castration- recurrent prostate cancer growth. A further goal was to identify EGF-mediated 
AR phosphorylation sites that contribute to AR transactivation in the absence of 
androgen, and the mechanisms by which mitogen signaling influences AR function, sub-
cellular localization and protein-protein interactions.  
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EXPERIMENTAL PROCEDURES 
 
CELL CULTURE MEDIUM 
CWR-R1 cells were maintained either in Richter’s improved minimal essential 
prostate growth medium (Irvine Scientific, Santa Ana, CA) or Dulbecco’s modified Eagle 
medium (DMEM, Gibco, Carlsbad, CA), each supplemented with 10 nM nicotinamide, 5 
µg/ml insulin, 5 µg/ml transferrin, 5 ng/ml selenium, 100 units/ml penicillin, 100 µg/ml 
streptomycin and 2% fetal bovine serum (FBS). DMEM growth medium was further 
supplemented with 15 mM HEPES, pH 7.2. LNCaP cells were maintained in RPMI 1640 
medium with 10% fetal bovine serum. LNCaP-C4-2 cells were grown in T media 
(DMEM:Ham’s F-12 with 5% fetal bovine serum, 5 µg/ml insulin, 13.65 pg/ml 
triiodothyronine, 5 µg/ml apo-transferrin, 0.244 µg/ml d-biotin, and 25 µg/ml adenine. 
LAPC-4 cells were cultured in RPMI-1640, 10% FBS, 100 units/ml penicillin, 200 mM 
L-glutamine, and 1nm R1881. XR-V15B cells were cultured in Ham's F10 with 2 mM L-
glut, 10% FBS and 100 units/ml penicillin. Monkey kidney (COS-1) cells were cultured 
in DMEM-H, 10% bovine calf serum, 100 units/ml penicillin, 200 mM L-glutamine and 
15 mM HEPES. Human endometrial Ishikawa cells were maintained in Eagle's minimum 
essential medium supplemented with 10% fetal bovine serum, 100 units/ml penicillin / 
streptomycin, and 2 mM L-glutamine.  
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RNA INTERFERENCE AND TRANSCRIPTION ASSAYS 
 
Duplex AR-siRNA-3 was ucaaggaacucgaucguauuu sense and 
auacgaucgaguuccuugauu antisense sequence, and AR-siRNA-4 was 
gaaaugauugcacuauugauu sense and ucaauagugcaaucauuucuu antisense sequence (NCBI 
M20132) (SMART selection designed siRNAs, Dharmacon Inc., Lafayette, CO). The 
control was siCONTROL nontargeting siRNA pool (Dharmacon Inc.). CWR-R1 prostate 
cancer cells derived from the CWR22 castration-recurrent prostate cancer xenograft (6, 
16) were transfected using Effectene (Qiagen, Valencia, CA) with 10 nM AR siRNA or 
control siRNA duplex and 0.1 µg mouse mammary tumor virus luciferase reporter 
(MMTV-Luc). CWR-R1 cells were plated (1.6 x 105 cells/well) in 12 well plates using 
Richter’s improved minimal essential prostate growth medium (Irvine Scientific, Santa 
Ana, CA) or Dulbecco’s modified Eagle medium (DMEM, Gibco, Carlsbad, CA), each 
supplemented with 10 nM nicotinamide, 5 µg/ml insulin, 5 µg/ml transferrin, 5 ng/ml 
selenium, 100 units/ml penicillin, 100 µg/ml streptomycin and 2% fetal bovine serum 
(FBS). DMEM growth medium was further supplemented with 15 mM HEPES, pH 7.2. 
DNA and siRNA (220 µl) containing per well, 45 µl EC buffer (Qiagen), 1 µl enhancer, 1 
µl Effectene reagent (Qiagen) and 200 µl 2% serum containing medium was added to cell 
cultures containing 0.8 ml fresh medium. The next day the medium was replaced with 
phenol red-free, serum-free Improved Minimal Essential Zinc Option medium 
(Gibco/Invitrogen) with and without DHT and EGF and incubations were continued for 
24 h. Human endometrial Ishikawa cells were transfected using FuGENE-6 (Roche 
Applied Science) as previously described (17) using 0.025 µg pCMV-AR and 0.1 µl 
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PSA-Enh-Luc. Cells were harvested in 0.25 ml lysis buffer containing 1% Triton-X-100, 
2 mM EDTA and 25 mM Tris-phosphate, pH 7.8 (18). Luciferase activity was 
determined using an automated LumiStar Galaxy multiwell plate reader luminometer 
(BMG Labtechnologies, Durham, NC). Transfection data are representative of at least 
three independent experiments. 
XRV15B TRANSIENT TRANSFECTION 
XRV15B cells were transfected using calcium phosphate DNA precipitation as 
described elsewhere (150). XRV15B cells (2.5x106 cells/6-cm dish) were transfected with 
1 µg pCMV-AR in the absence and presence of 4 µg pCDNA-Ku80, and 4 µg MMTV-
Luc wild-type (wt), ∆-381:-394, or ∆-421:-364 as indicated. After transfection, XRV15B 
cells were placed in serum-free, phenol red-free medium in the absence and presence of 1 
nM DHT.  The next day, the media with and without DHT were exchanged, and 24 h later  
luciferase activity was measured. 
CELL GROWTH ASSAYS 
CWR-R1 prostate cancer cells (1.6 x 105/well) in 12-well plates were allowed to 
grow in prostate growth medium for 24 h. Cells were infected with 103 viral particles/cell 
in medium containing 2% FBS by rocking for 30 min at room temperature, and incubated 
overnight at 37˚C in serum containing medium. Cells were transferred to serum-free, 
phenol-red free medium in the absence and presence of DHT and EGF. Duplicate wells 
were treated and assayed on days 1, 3 and 5 after infection. One-tenth volume of 2- (2-
methoxy- 4- nitrophenyl)- 3- (4- nitrophenyl)- 5- (2, 4- disulfo- phenyl)- 2H- tetrazolium 
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monosodium salt (WST-8, Dojindo Molecular Technologies, Gaithersburg, MD) was 
added to the wells, incubated for 2.5 h at 37˚C and absorbance determined at 450 nm 
using a plate reader. The effect of inhibiting protein kinase C (PKC) on cell proliferation 
was assayed using cells plated in medium containing 2% FBS. The next day, cells were 
treated with calphostin (Calbiochem, La Jolla, CA), a PKC inhibitor, in the absence and 
presence of EGF. Proliferation assays were performed 1, 3, 5 and 7 days after treatment 
(Figure 2.1)  
MOLECULAR CLONING AND CHARACTERIZATION OF SCAAV VECTORS  
pSilencer 1.0-U6 siRNA containing an RNA polymerase III promoter (14, 19) 
(Ambion Inc., Austin, TX) and the Insert Design Tool for the pSilencer Vectors 
(Ambion) were used to generate hairpin siRNA encoding DNA oligonucleotide 
sequences based on the siRNA-3 sequence (Figure 2.2). A central loop sequence 
ttcaagaga and single overhang strand were added for cloning. Oligonucleotides that target 
AR were aaggaactcgatcgtatcattcaagagatgatacgatcgagttccttgatttttt sense (55 nucleotides) 
and aattaaaaaatcaaggaactcgatcgtatcatctcttgaatgatacgatcgagttccttggcc antisense sequence 
(63 nucleotides) with 5´ EcoRI and 3´ ApaI terminal restriction sites.  Control scAAV 
duplex oligonucleotides were ttctccgaacgtgtcacgtttcaagagaacgtgacacgttcggagaatttttt sense 
(53 nucleotides) and aattaaaaaattctccgaacgtgtcacgttctcttgaaacgtgacacgttcggagaaggcc 
antisense sequence (61 nucleotides). Oligonucleotides were annealed by incubating at 
90ºC for 3 min in the presence of 46 µl 
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annealing buffer containing 100 mM K-acetate, 2 mM sodium acetate and 0.03 M 
HEPES, pH 7.4, followed by 1 h incubation at 37ºC. pSilencer 1.0-U6 was linearized 
with ApaI and EcoRI and ligated overnight at 25ºC to the siRNA insert. The type II 
scAAV expression vectors ptrs-U1a-RFP-U6 and ptrs-U1a-green fluorescent protein and 
helper plasmids pXX6 (adenoviral helper genes) and pXX2 (AAV helper genes) were 
generously provided by Douglas M. McCarthy and Jude R. Samulski (Gene Therapy 
Center, University of North Carolina at Chapel Hill). p-trs-U1a-RFP-U6 contains a small 
nuclear RNA U1a promoter to drive expression of red fluorescent protein derived from 
pDSRED2-C1 (Clontech, Palo Alto, CA). The U6 promoter and duplex sequences were 
excised from pSilencer 1.0-U6 and cloned into ptrs-U1a-RFP-U6 linearized with NotI 
and KpnI. In frame ligation was confirmed by sequencing. scAAV vectors produced in 
human embryonic kidney 293 cells using three-plasmid transfection were purified as 
described previously (20).  
Human embryonic kidney 293 cells (2 x 107/dish) in DMEM containing 10% FBS 
were plated in twenty 15 cm dishes for 70-80% confluency after 24 h. Each plate was 
passaged 1:4 in 15 cm dishes and 16 h later, the medium was replaced with complete 
Iscove’s modified Dulbecco’s medium (Invitrogen, Carlsbad, CA) containing 10% FBS, 
and incubated for 3 h before transfection. pXX6 helper plasmid (90 µg) was combined 
with 30 µg control or AR-siRNA-scAAV vector plasmid, 30 µg pXX2 helper plasmid, 
0.25 M CaCl2, 0.25 M NaCl, 1.5 mM sodium phosphate and 0.05 M HEPES, pH 7.2. 
Cells were incubated for 24 h and medium was replaced with DMEM containing 2% 
FBS. Virus was collected 48 h post-transfection by lysing cells using 3 freeze-thaw 
cycles. scAAV vectors were purified by isopycnic centrifugation in CsCl (ρ 1.4 g/ml) in 
an SW41 rotor (Beckman, Palo Alto, CA) at 40,000 rpm for 48 h at 10ºC. Fractions were 
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collected, semi-quantitated by slot-blot and peak fractions pooled and dialyzed in 
phosphate buffered saline (PBS) overnight at 4ºC (Figure 2.3). To test transduction 
efficiency of the scAAV serotype II in CWR-R1 cells, cells were infected with a scAAV 
type II ptrs-U1a-green fluorescent protein virus in medium containing 2% FBS. Cells 
were harvested 1 and 9 days post-infection. Green fluorescent protein expression in 
transduced cells was analyzed by fluorescence-activated cell sorting using a FACScan1 
cytometer (Becton-Dickinson). Forward and side scatter parameters were set according to 
cell size, and the setting for fluorochrome detection adjusted so that fluorescence 
intensity of uninfected negative control cells was within the first decade of the 4 scale log 
plot. 
SCAAV INFECTION OF PROSTATE CANCER CELL LINES 
CWR-R1 prostate cancer cells (1.6 x 105/well) in 12-well plates were allowed to 
grow in prostate growth medium for 24 h. Cells were infected with 103 viral particles/cell 
in medium containing 2% FBS by rocking for 30 min at room temperature (unless 
indicated otherwise) and incubated overnight at 37˚C in serum containing medium. Cells 
were transferred to serum free, phenol-red free medium in the absence and presence of 
DHT and EGF. Duplicate wells were treated and assayed on days 1, 3 and 5 after 
infection. One-tenth volume of 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-
disulfo-phenyl)-2H-tetrazolium monosodium salt (WST-8, Dojindo Molecular 
Technologies, Gaithersburg, MD) was added to the wells, incubated for 2.5 h and 
absorbance determined at 450 nm using a plate reader. The effect of inhibiting protein 
kinase C (PKC) on cell proliferation was assayed using cells plated in medium containing 
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2% FBS. The next day, cells were treated with Calphostin (Calbiochem, La Jolla, CA), a 
PKC inhibitor, in the absence and presence of EGF. Proliferation assays were performed 
1, 3, 5 and 7 days after treatment.  
 
PLASMIDS AND SITE-DIRECTED MUTAGENESIS 
 
Expression vectors pCMVhAR for full-length human AR (21), pCMVhAR-(1-
660) for the AR NH2-terminal, DNA binding and hinge regions, and AR-(507-660) for 
part of the AR NH2-terminal domain with DNA binding domain and hinge region, were 
described previously (1, 22). Mutations in pCMVhAR were generated by PCR 
amplification and verified by sequencing. Flag-AR-(507-660) was created by subcloning 
pCMVhAR mutants into EcoRI and SalI digested pCMV-Flagb. Glutathione-S-
transferase (GST) fusion vector GST-AR-(1-660) was prepared as described previously 
(23). GST-AR-(1-660)-S578A was generated by site directed mutagenesis using the 
QuikChange kit (Stratagene) and confirmed by sequencing. Prostate specific antigen 
enhancer luciferase reporter vector (PSA-Enh-Luc) was provided by Michael Carey 
(University of California, Los Angeles) and contains the PSA upstream enhancer region 
(24). MMTV-Luc was provided by Stanley M. Hollenberg and Ron M. Evans (Salk 
Institute).  
NORTHERN BLOTTING  
CWR-R1 cells (5 x 106/10-cm dish) were plated in prostate growth medium 
lacking EGF. The next day, cells were washed with phosphate-buffered saline, and the 
medium was changed to phenol red-free improved MEM zinc option (Invitrogen) 
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containing 0.2% albumin (AlbuMax I;  Invitrogen ). After an overnight incubation, cells 
were treated without or with 100 ng/ml EGF for 24 h in the same medium prior to RNA 
isolation using Trizol Reagent (Invitrogen ) according to the manufacturer's instructions. 
RNA (15 µg) aliquots were fractionated on 1% agarose gels, transferred to nylon 
membranes, and hybridized with 32P-labeled pSG5TIF2 BamHI fragment containing 
nucleotides 629-869 and a pGEM-18S-4 (Promega) Sp6-generated fragment for control 
18 S ribosomal RNA. 
REAL-TIME REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION  
1.6x106 LacZ- or ∆-TR-transduced CWR-R1 cells were plated in prostate growth 
medium lacking EGF, serum-starved for 24 h and treated with or without 0.1nM DHT. 
To determine EGF mRNA levels in CWR-R1 cells, one day after plating, cells were 
serum starved for 24 h and the next day treated for 2, 5, 8 or 24 h with or without 10 
ng/ml EGF. For EGF mRNA expression studies, 1.6x106  CWR-R1 cells were plated, 
serum starved for 24 h and treated the next day with 0.1, 1 or 10 nM DHT. Cells were 
washed in PBS, harvested and mRNA extracted and purified (RNeasy® Midi Kit, 
Quiagen, Valencia, CA). RNA quality was verified (Agilent LabChip Bioanalyzer, UNC-
CH Genomics Core) and quantitative one-step-reverse transcriptase (RT)-realtime PCR 
was performed (Light Cycler System, Roche). The housekeeping gene human β-
glucuronidase (GusB) was used to perform relative quantification. Standard curves for 
GusB, hK2, and EGF transcription were generated and efficiencies were calculated to 
validate GusB as a suitable housekeeping gene for data normalization. The following 
primer and probe sequences were used: hK2 forward 5’-
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GCCTTAGACCAGATGAAGACTCCA-3’; hK2 Reverse, 5’-
CCCAGGACCTTCACAACATC-3’; hK2 Probe, 5’-6-FAM-
TGACCTCATGCTGCTCCGCCTGT-BHQ-1-3’ (81). GUSB Forward, 5’-
GGTGCTGAGGATTGGCA-3’; GusB Reverse 5’-TAGCGTGTCGACCCCATTC-3’; 
GUSB probe, 5’-6-FAM-TGCCCATTCCTATGCCATCGTGTG-TAMRA-3’ (GUSB 
sequences kindly provided by Dr. Sergio Onate, Roswell Park Cancer Institute); EGF 
Forward, 5'-CTGTACTCTTGGGTGT-3'; EGF Reverse 5'-
AGCAATCACATTCCCAGGAT-3'; EGF Probe 5'-6-FAM-
AGGATTTGTTCTGCTTCCTGATGGGA-TAMRA-3' (151). Samples were run in 
duplicate and the hK2/GUSB ratio was used to compare the effects of DHT on hK2 
transcription in two independent experiments.  
IN VITRO KINASE ASSAYS 
 
GST-AR-(1-660) and GST-AR-(1-660)-S578A were expressed in BL21 
Escherichia coli cells treated with 1 mM isopropyl-β-thiogalactoside for 24 h at 16ºC 
during log phase growth. Glutathione-agarose beads (Amersham, Pharmacia Biotech 
Piscataway, NJ) were incubated for 1 h at 4ºC with sonicated bacterial supernatants 
containing GST-AR fusion proteins. Beads were washed 3 times with PBS containing 1% 
Triton-X-100, followed by 3 washes with kinase buffer containing 10 mM EGTA, 0.1 M 
MgCl2 and 0.4 M 2-(N-morpholino) ethanesulfonic acid, pH 6.0. Part of the sample 
eluted with sample buffer was analyzed on 8–12% acrylamide gradient gels containing 
SDS. A serial dilution of bovine serum albumin was analyzed in parallel to estimate 
protein recovery. Bound protein (10–15 µg) was assayed for PKC phosphorylation. GST 
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beads were resuspended in 30 µl kinase buffer containing 10 or 100 µCi [γ-32P] 
adenosine triphosphate (3000 Ci/mmol) and 20 ng purified PKC (catalytic subunit, rat 
brain, Calbiochem, San Diego, CA) in the absence and presence of 1 µM unlabeled 
adenosine triphosphate and either 2.5 µg histone-H1 or 2.5 µg wild-type or mutant GST-
AR-(1-660) fusion protein. After 10 min at 30ºC, reaction products were resolved on 8–
12% acrylamide gradient gels containing SDS, which were dried and analyzed by 
autoradiography. To verify equal loading, gels were rehydrated in PBS and stained with 
Coomassie blue or half of the input resin was resuspended in 2X SDS sample buffer and 
analyzed by immunoblotting using AR52 antibody. Autoradiographs were quantitated by 
densitometric scanning using Image-Pro Analyzer Software (Media Cybernetics, Inc., 
Bethesda, MD). 
 
WESTERN BLOTTING AND IMMUNOPRECIPITATION 
 
AR phospho-Ser-578 antipeptide antibody was raised in rabbits (21st Century Bio, 
Marlboro, MA) by immunizing with two bovine serum albumin-coupled peptides that 
were based on human AR sequence 572GALTCGSCKVFFKRA586. Peptide 1 was acetyl-
G[pS]-aminobutyrate-KVFFKRA-amino-hexanoic acid-C-amide. Peptide 2 was acetyl-
C-aminohexanoic acid-GALT-aminobutyrate-G[pS]-aminobutyrate-KVFF KRA-amide. 
Nonphospho-peptide acetyl-C-amino-hexanoic acid-GALT-amino-butyrate-GS-amino-
butyrate-KVFFKRA-amide was used to establish binding specificity. Aminobutyrate 
replaced cysteine to avoid disulfide bonding, aminohexanoic acid was a 6 carbon spacer, 
and the carboxyl-terminal cysteine was coupled to bovine serum albumin.  
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Immunoblotting was performed using monkey kidney COS-1 cells maintained in DMEM 
containing 2 mM L-glutamine, 10% bovine calf serum, penicillin, streptomycin and 20 
mM HEPES, pH 7.2. COS cells (2.5 x 106/10 cm dish) were transfected with 2 µg DNA 
using DEAE dextran (25). Cells were treated 24 h after transfection with and without 10 
ng/ml EGF for 5 h. For MAP kinase inhibition studies, cells were treated for 1 h before 
transfection with and without U0126 (Promega). The next day cells were serum-starved 
in the absence and presence of U0126 and media replaced 24 h later with and without 10 
ng/ml EGF for 5 h. Cells were rinsed with PBS, scraped into 1.5 ml cold PBS and 
centrifuged at 12,000xg for 2 min. The buffer was aspirated and cells were resuspended 
and vortexed for 10 sec in 50–100 µl buffer containing 1% Nonidet P-40, 0.15 M NaCl, 
1% sodium deoxycholate, 0.1% SDS, 0.5 mM EDTA, 50 mM Tris-HCl, pH 7.5, 0.02 
mg/ml pancreas extract, 1 mM phenylmethylsulfonyl fluoride, 0.005 mg/ml pronase, 
0.0005 mg/ml thermolysin, 0.003 mg/ml chymotrypsin and 0.33 mg/ml papain (Roche 
Applied Science). After a 15 min incubation on ice, lysates were centrifuged for 15 min 
at 20,000xg and protein concentrations determined using the Bio-Rad assay. Protein (25 
µg) was incubated with and without 2.5 units λ-phosphatase (Sigma) in phosphatase 
buffer (Sigma) containing 2 mM MnCl2. To inhibit λ-phosphatase activity, lysates were 
incubated with 2.5 mM sodium vanadate, 10 mM sodium fluoride and phosphatase 
Cocktail Inhibitors 1/2 (Sigma) for 30 min at 25ºC.  
To express Flag-tagged constructs in CWR-R1 cells, 3 µg DNA/5 x 106 cells/10 
cm dish was transfected using Effectene (Qiagen). The next day CWR-R1 cells were 
treated with and without 10 ng/ml EGF for 5 h, harvested in cold PBS from 5 pooled 
dishes for each treatment group and lysed in immunoprecipitation buffer containing 0.5% 
Nonidet P-40, 10% glycerol, 0.05 M sodium fluoride, 0.15 M NaCl, 50 mM Tris-HCl, pH 
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7.6, and phosphatase and protease inhibitors. For immunoprecipitation of full-length AR 
expressed in COS cells, 0.5 µM DHT was added to the lysis buffer. Approximately 1 mg 
protein from two 10 cm COS cell dishes was precleared using Sepharose CL-4B (Sigma) 
and immunoprecipitated using anti-FLAG M2 Affinity Resin (Sigma). The final pellets 
were washed 3 times with immunoprecipitation buffer with and without 0.5 µM DHT and 
resuspended in 60 µl 2X sample buffer containing 3.3% SDS, 10% glycerol, 0.2% 2-
mercaptoethanol and 20 mM Tris-HCl, pH 6.8 and analyzed by immunoblot. For 
immunoblots of cell extracts, 4% total protein was separated on 10% acrylamide gels 
containing SDS. After electrophoresis, gel proteins were electroblotted to Immobilon-P 
membrane (Millipore Corp., Bedford, MA) overnight. Transfer blots were blocked 
overnight at 4ºC in 5% milk, 0.9% NaCl, 0.05% Tween-20 and 0.01 M Tris-HCl, pH 7.5. 
Blots were incubated for 1–2 h with 2.5 µg/ml rabbit polyclonal AR52 antibody targeting 
human AR NH2-terminal amino acid residues 544 to 558 (21), anti-Flag M2 monoclonal 
antibody (1:2000 dilution, F-3165 Sigma), ß-actin antibody AC-15 (1:5000 dilution, 
Abcam, Inc.) or Ku (p70) and Ku (p80) antibodies (0.5 µg/ml, MS-329 and MS-285, Lab 
Vision Corporation, Fremont, CA). Anti-rabbit or anti-mouse horseradish peroxidase-
conjugated secondary IgG antibodies (1:10,000 dilution, Amersham Life Sciences) were 
incubated for 30 min at room temperature. Signals were detected using 
chemiluminescence (SuperSignal West Dura Extended Duration Substrate, Pierce, 
Rockford, IL).  
Reactivity of AR phospho-Ser-578 antisera was determined by immunoblot of 
BSA, BSA-coupled AR-(572-586) non-phosphorylated peptide and AR-(572-586) 
phospho-Ser-578 peptides 1 and 2 immunogens, and wild-type Flag-AR-(507-660) and 
the S578A mutant. COS cells (2.5 x 106/10 cm dish) were transfected with 2 µg wild-type 
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Flag-AR-(507-660) and the S578A mutant, and 24 h later cells were placed in serum-
free, phenol-red free media for 24 h, and treated with and without 10 ng/ml EGF for 5 h. 
Cells were lysed in immunoprecipitation buffer containing phosphatase and protease 
inhibitors and immunoprecipitated using anti-FLAG M2 affinity resin (Sigma) and 
resolved on a 12% acrylamide gel containing SDS. Transfer blots were probed with AR 
phospho-Ser-578 antisera (1:100 dilution) and 2.5 µg/ml AR52 antibody at room 
temperature for 2 h and with secondary antibody as described above. After 
chemiluminescence detection, membranes were rinsed with distilled water and incubated 
for 10 min at room temperature with 0.2% Ponceau-S in 0.1% glacial acetic acid. 
IMMUNOCYTOCHEMISTRY 
 
Immunocytochemistry was performed in COS cells (1 × 105 cells/well) in 12 well 
plates with a coverglass (26). Cells were transfected using Effectene with 0.2 µg wild-type 
Flag-AR-(507-660) or the S578A mutant and serum starved 24 h. Cells were fixed for 10 min 
at room temperature with 4% paraformaldehyde in PBS, permeabilized for 5 min at 4°C with 
0.2% Triton-X-100 in PBS, blocked for 1 h at room temperature with 0.5% bovine serum 
albumin in PBS (13), and incubated for 1 h in 0.5% bovine serum albumin containing AR52 
antibody (2.5 µg/ml) and for 30 min at room temperature with fluorescent-(FITC)-conjugated 
anti-rabbit secondary antibody (1:75 dilution, Jackson ImmunoResearch Laboratories, Inc.). 
Slides were viewed using an Olympus BX60 microscope with original magnification of 40X. 
NUCLEAR/CYTOPLASMIC EXTRACTION 
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Flag-AR fusion vectors were transfected into COS cells (2.5 x 106/10 cm dish) 
using DEAE dextran. The next day cells were serum starved and 24 h later treated with 10 
ng/ml EGF for 5 h. Nuclear extracts were prepared using the Nuclear Extract Kit (Active 
Motif, Carlsbad, CA). Cells were washed with ice-cold PBS containing phosphatase 
inhibitors, scraped and pelleted for 5 min at 2600xg, resuspended in 550 µl hypotonic 
buffer and incubated 15 min on ice. Detergent (25 µl) was added and samples were 
vortexed 10 sec at the highest setting. Cell suspensions were centrifuged for 30 sec at 
14,000xg and cytoplasmic extracts were stored at -80ºC. Nuclear cell pellets were 
resuspended in 50 µl complete lysis buffer containing 1 mM DTT and protease inhibitor 
cocktail. Lysates were vortexed for 10 sec and suspensions incubated for 30 min on ice on 
a rocking platform at 4ºC. Extracts were vortexed 30 sec, centrifuged 10 min at 14,000xg 
and nuclear fractions transferred to pre-chilled microcentrifuge tubes. Protein concentration 
was determined and nuclear and cytoplasmic extracts analyzed by immunoblotting using 
2.5 µg/ml AR52, tubulin-α (2 µg/ml, Thermo Fisher scientific, Fremont, CA) and Laminin 
B1 antibodies (2 µg/ml, Active Motif, Carlsbad, CA).  
 
 
 
 43 
 
RESULTS 
 
ANALYSIS OF EGF REGULATION OF TIF2 MRNA IN CWR-R1 CELLS 
 
We showed previously that progression to recurrent growth of prostate cancer is 
associated with increased levels of p160 coactivators (49,79) that increase AR activity 
(48). We also demonstrated that steady state levels of TIF2 protein were highest in the 
CWR-R1 cell line compared with PC3, LNCaP, and LNCaP-C4-2 prostate cancer cell 
lines, and HeLa cells (48). TIF2 was undetectable in a nontransformed human foreskin 
fibroblast cell line and lower levels of TIF2 were detected in COS and CV1 cells 
compared to the prostate cancer cell lines. To test whether the EGF-mediated increase in 
AR protein was at the level of transcriptional regulation, we performed northern blot 
analysis in CWR-R1 cells. We ruled out a direct effect of EGF on TIF2 transcription, 
since northern blot analysis showed similar levels of TIF2 mRNA in CWR-R1 cells with 
and without EGF treatment (79) (Fig. 3.1). These data suggest that EGF regulation of 
TIF2 coactivation is not at the transcriptional level.  Our published data indicate that EGF 
signaling through MAP kinase increases TIF2 coactivation of AR transactivation in 
recurrent prostate cancer (79). 
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TIF2- MEDIATED AR TRANSCRIPTIONAL ACTIVATION 
 
To determine whether TIF2/GRIP1 is required for AR transactivation induced by 
DHT and EGF in CWR-R1 cells, we used RNA interference to inhibit endogenous 
TIF2/GRIP1 expression. An siRNA mixture consisting of 12-30 base pairs double-
stranded RNA coding for TIF2/GRIP1 was transiently transfected into CWR-R1 cells 
together with pCMVhAR and PSA-Enh-Luc. TIF2 siRNA directed at nucleotides 197-
376 inhibited AR transactivation of PSA-Enh-Luc by 5-fold, whereas a glyceraldehyde-3-
phosphate dehydrogenase siRNA mixture had no effect (Fig. 3.2). Specificity for the TIF2 
siRNA inhibition was established by cotransfecting pSG5-TIF2 with 10 nM TIF2 siRNA. 
Partial recovery of AR transactivation of PSA-Enh-Luc activity in the presence of 
overexpressed TIF2 provided evidence that inhibition by TIF2 siRNA was specific.  
The data suggests that, in conditions of androgen deprivation, there is a direct link 
between AR transcriptional activity, increased p160 coactivator levels and EGF signaling 
in recurrent prostate cancer. 
DOMINANT NEGATIVE  INHIBITION OF AR TRANSACTIVATION 
 
To study the role of AR in CWR-R1 cells, a dominant negative approach was 
used. AR∆142-337 contains a deletion in the NH2-terminal region that results in loss of 
AR transactivational activity and inhibits wild-type AR possibly due to dimerization and 
loss of binding of one or more coactivators. Transient transfection of CWR-R1 cells with 
AR∆142-337 decreased DHT and DHT plus EGF-mediated MMTV-Luc transcription, 
MMTV contains an AR target promoter and it is transactivated by endogenous AR. 
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CWR-R1 cells (Fig. 3.3).  Suppression of AR using AR∆142-337 delivered via lentiviral 
vectors was used to test the hypothesis that prostate cancer recurrence can be delayed or 
prevented by interfering with AR function. Our unpublished studies show that lentiviral 
vectors can achieve high level expression of AR∆137-142, decrease plasmid luciferase 
expression from the MMTV promoter, and decrease CWR-R1 cell proliferation in 
culture. Studies are underway to determine the role of AR in CWR-R1 tumor formation 
in vivo. 
HUMAN KALLIKREIN 2 (HK2) AS A MARKER OF ANDROGEN REGULATED GENE 
TRANSCRIPTION 
 
Insulin-like growth factor binding protein-5 (IGFBP5), homeobox gene Nkx 3.1, 
AR coactivator ARA-70, human kallikrein 2 (hK2) and cell cycle genes Cdk1 and Cdk2 
are androgen regulated in the CWR22 human prostate cancer xenograft (50). The PSA-
Enh-Luc reporter gene is activated only weakly in CWR-R1 cells. We explored genes 
containing AREs to determine a marker of endogenous AR activity in CWR-R1 cells. In 
light of the fact that hK2 is useful in clinical diagnosis and prognosis of prostate cancer 
(152) and that an ARE in the 5′ far upstream promoter region of the hK2 gene was 
identified as crucial for its regulation in LNCaP cells (153), we measured hK2 mRNA 
levels in the absence and presence of DHT.  
To demonstrate that AR∆142-337 inhibits endogenous AR in the CWR1 recurrent 
prostate cancer cell line, we performed gene profile studies of these candidate genes.  
Northern blots suggested that hK2 levels increased ~2 fold in response to androgen in 
CWR-R1 cells. To confirm this, LacZ-transduced CWR-R1 cells were 
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seeded, serum-starved for 24h and treated with or without 0.1nM DHT and harvested for 
one-step real time-RT PCR analysis. Results indicate 2-fold induction of hK2 mRNA 
(Fig. 3.4) in response to DHT suggesting hK2 transcription is a marker of AR 
transcriptional activity in the recurrent CWR-R1 cancer cell line.  
Our data indicate that in CWR-R1 cells hK2 may be a suitable gene for studies 
involving endogenous AR activity in castration-recurrent cell lines. Improving the 
accuracy of testing for prostate cancer by combining the conventional PSA test with PSA 
derivatives or with other markers, such as hK2, could improve the current PSA test to 
accurately estimate cancer volume and preoperative staging.  
SIRNA-MEDIATED  INHIBITION OF AR EXPRESSION AND TRANSACTIVATION 
 
As an alternative approach to inhibiting endogenous AR, siRNA targeting AR 
was used to determine the requirement for AR transcriptional activation.  Four siRNA 
duplexes targeting AR mRNA sequence were transfected into CWR-R1 cells to inhibit 
AR-mediated transcriptional activation of the MMTV-Luc reporter gene. As expected, 
DHT increased AR transcriptional activity ~100-fold, with a further 3-fold increase after 
addition of EGF (Fig. 3.5). A similar effect of DHT with and without EGF on AR 
transcriptional activity was seen after transfection of a control siRNA oligonucleotide 
that did not reduce AR levels (Fig. 3.5A and 3.5B, lane 5). However, AR targeted siRNA 
oligonucleotide-3 that reduced AR levels (Figure 3.5B, lane 3) greatly reduced AR 
transactivation, with only a 2-fold increase in activity remaining in the presence of DHT 
and a ~12 fold increase in response to DHT and EGF (Fig. 3.5A). 
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Duplex 3 targeted an RNA sequence complementary to the hinge region of the AR and 
was used for subsequent cloning in viral vectors.  
GENERATION AND CHARACTERIZATION OF AR-SIRNA-SCAAV AND CONTROL-SIRNA-
SCAAV  
 
A scAAV type II was generated to target endogenous AR protein in CWR-R1 
cells as indicated in the “Experimental Procedures” section. Slot blot analysis was 
performed to confirm viral titer (Figure 3.6A). To evaluate transduction efficiency of the 
virus, flow cytometry was performed on infected CWR-R1 cells. Viral particles (103 and 
104 ) were used as the initial titer per cell. A green fluorescent protein (GFP) containing 
scAAV serotype II (p-hpa-trs-SKAAV2) was used for flow cytometry analysis. One day 
after infection ~72% of the cells were GFP positive at a viral dose of 104 and ~83% GFP 
positive using 103 viral particles/cell. 
To characterize additional infectivity properties of the virus in CWR-R1 cells, 
cells were plated in L-Polylysine-coated plates. Transduction efficiency was significantly 
reduced as only ~28% of the cells were GFP positive at 103 virus particles/cell 24 h after 
infection.To evaluate the timing of transduction, cells were left in culture after infection 
for 9 days and flow cytometry was performed. At 103 virus particles/cell the GFP positive 
cell population decreased about  ~62% from initial infection demonstrating that, due to 
the episomal mechanism of viral transduction, transgene expression was lost in the 
cultured cells. To explore optimal methods for scAAV transduction, experiments were 
performed by infecting cells without inoculation of the virus-containing media. Flow 
cytometry showed ~80% transduction efficiency. 
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infection (Fig. 3.6B, third panel). Western blots were performed 5 days after infection in 
CWR-R1 cells (Fig. 3.7). The data indicate transduction of scAAV-siRNA under these 
conditions results in partial inhibition of AR expression 2 days after infection of CWR-
R1 cells.  
scAAV uptake and transduction varies among cell types. To test whether the 
scAAV-ARsiRNA inhibited endogenous AR expression in prostate cancer cell lines 
LNCaP, LNCaP-C42 and LAPC4 cells were infected with the scAAV-CTR or scAAV-
ARsiRNA. 48 h after infection, AR protein expression was decreased in the presence and 
absence of DHT (Fig. 3.8 A-C). These data validate scAAV as a mechanism for siRNA 
delivery and AR protein inhibition in several prostate cancer cell lines. This tool can be 
used in investigating the role of AR in prostate cancer progression and recurrence in 
vitro.  
AR-DEPENDENT CWR-R1 PROSTATE CANCER CELL PROLIFERATION 
 
We investigated the requirement for AR in castration-recurrent prostate cancer cell 
growth by performing proliferation studies using CWR-R1 cells infected with control or AR 
targeted siRNA-scAAV in the absence and presence of DHT and/or EGF. CWR-R1 cells 
were infected and viral containing media inoculated prior to incubation form 30 min at room 
temperature. AR-siRNA-scAAV infected cells grew more slowly than control cells in the 
absence and presence of 0.1 nM DHT (Figure 3.9A). The >90% reduction in AR levels in 
CWR-R1 cells treated without (Figure 3.9B, upper panel) and with DHT (Figure 3.9B, lower 
panel) assayed by immunoblot 2 and 5 days after AR-siRNA-scAAV infection suggested that 
CWR-R1 cell growth was stimulated by AR both in the absence and presence of androgen.  
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EGF also stimulated control CWR-R1 cells to grow faster than cells infected with AR-
siRNA-scAAV (Figure 3.10A, left panel). The reduction in AR levels determined by 
immunoblot of EGF treated CWR-R1 cells 2 and 5 days after AR-siRNA-scAAV 
infection (Figure 3.10A, right panel) provided evidence that EGF stimulation of CWR-R1 
cell growth was mediated in part by AR. However, the attenuated but significant growth 
response of AR-siRNA-scAAV infected cells to EGF suggested that EGF also stimulated 
cell proliferation through signaling mechanisms that are independent of AR. The 
stimulatory effect of EGF together with DHT on growth of control and AR-siRNA-
scAAV infected cells was greater than either hormone alone and approached maximal 
levels within 3 days (Figure 3.10B, left panel). Growth of AR-siRNA-scAAV infected 
cells treated with DHT and EGF was less attenuated compared to control cells, even 
though AR levels were reduced as shown by immunoblot (Figure 3.10B, right panel). The 
results indicate that AR increases CWR-R1 prostate cancer cell growth in response to 
DHT or EGF, and that EGF and DHT act synergistically through AR.  
ANDROGEN-INDEPENDENT AR TRANSACTIVATION AND EGF-MEDIATED INCREASE IN 
FLAG-(AR507-660)  EXPRESSION 
 
To pursue evidence that AR functions in castration-recurrent prostate cancer in 
the absence of androgen, we tested whether EGF can increase endogenous AR 
transcriptional activity in CWR-R1 cells using an MMTV-Luc reporter vector in the 
absence of DHT. In response to EGF alone, the ~3 fold increase in AR transcriptional 
activity in the presence of control siRNA was abrogated by AR duplex siRNA 
oligonucleotide-3 (Figure 3.11). The results indicate that EGF can activate AR in the 
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CWR-R1 prostate cancer cell line in the absence of androgen and that EGF and DHT act 
synergistically to increase AR transcriptional activity. These data, together with the cell 
growth studies presented above, support the hypothesis that AR activation by EGF is 
sufficient to drive prostate cancer cell growth.  
To determine whether EGF directly affects AR expression, western blots were 
performed in COS cells expressing pCMV-AR507-660.  An EGF-dependent increase of 
pCMV-AR507-660 was evidenced up to 10 h after the onset of treatment (Figure 3.12, 
left panel). To verify that the effects were not due to EGF effects on the CMV promoter, 
pCMV-Flag-CHIP was transfected into COS cells and treated with EGF. The similar 
levels of pCMV-Flag-CHIP suggest that EGF effects were independent of the CMV 
promoter. These data indicate that there are in a time dependent effects of EGF on AR 
and post-transcriptional modifications that may play a role on AR transcriptional activity. 
REAL-TIME RT-PCR ANALYSIS OF ANDROGEN-MEDIATED REGULATION OF EGF 
TRANSCRIPTION 
 
Prostate cancer cell lines have been shown to synthesize and secrete EGF and 
related peptides (154). Recurrent CWR22 tumors express high levels of EGF-related 
ligands compared with the androgen-dependent (98), and increased immunostaining of 
TGF-α was found in recurrent CWR22 xenografts (155). To determine whether EGF was 
androgen-regulated in CWR-R1 cells, real-time PCR analysis was performed in the 
presence and absence of 0.1 nM DHT. Standard curves were generated for EGF and 
human GUSB (beta-glucuronidase) genes using fluorescent probes in a one-step reverse 
transcription real-time PCR reaction. Efficiency coefficients for the two genes were 
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calculated and relative quantitation was performed to compare the normalized cross point 
values for EGF. We found that EGF expression in CWR-R1 cells (Figure 3.13) was not 
androgen regulated. This suggests that EGF mediated effects in CWR-R1 cells are not 
due to increased EGF transcription under conditions of androgen deprivation.  
EGF DEPENDENT PHOSPHORYLATION WITHIN THE AR NH2-TERMINAL AND DNA 
BINDING DOMAIN (DBD) FRAGMENT AR-(507-660) 
 
Sequence analysis using NetPhos 2.0 (27) indicated 15 consensus serine, 
threonine or tyrosine phosphorylation sites between AR residues 507-660 that comprise 
part of the AR NH2-terminal region, the DNA binding domain and hinge region (Figure 
3.14 A). Immunoblots of wild-type Flag-AR-(507-660) expressed in COS cells revealed a 
21 kDa protein, and after treatment with EGF, an additional slower migrating 23 kDa 
form (Figure 3.14B, lanes 1–3). The EGF dependent slower migrating form was 
eliminated by treatment with λ-phosphatase in the absence, but not in the presence of 
phosphatase inhibitors (Figure 3.14 B, lanes 3–8). The slower migrating 23 kDa band was 
also observed in response to EGF with Flag-AR-(507-660)-C576A, which has a cysteine 
mutation in the first zinc module that eliminates DNA binding (see data in Figure 3.21, 
lanes 3–4). The appearance of an EGF-dependent and phosphatase-sensitive slower 
migrating form of Flag-AR-(507-660) indicated that EGF induces phosphorylation at one 
or more sites between AR residues 507-660 independent of AR binding to DNA.  
To identify the EGF-dependent AR phosphorylation site(s), single serine or 
threonine to alanine and tyrosine to phenylalanine mutations were introduced into Flag-
AR-(507-660) at the consensus phosphorylation sites highlighted in Figure 3.14A. 
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Immunoblots of cell extracts before and after treatment with EGF indicated that only the 
AR NH2-terminal MAP kinase consensus S515A mutation eliminated the slower 
migrating 23 kDa form of Flag-AR-(507-660) when assayed in COS and CWR-R1 cells 
(Figure 3.15A, lanes 1–4). This result provided evidence that AR is phosphorylated at 
Ser-515 in response to EGF. In addition, the PKC consensus site mutation S578A in the 
AR DNA binding domain increased the relative proportion of the slower migrating 
23kDa phospho-Ser-515 form in the presence of EGF (Figure 3.15 A, lanes 5-6). MAP 
kinase dependent phosphorylation at AR Ser-515 was supported by the decrease in 
intensity of the slower migrating 23 kDa band after treatment with both EGF and 
increasing concentrations of the MAP kinase inhibitor, U0126 (Figure 3.15 B).  
AR phosphorylation at Ser-578 was indicated by the reactivity of an AR phospho-
Ser-578 specific antibody that recognized two AR-(572-586) phospho-Ser-578 
conjugated peptides used as immunogens but not unphosphorylated AR-(572-586) 
(Figure 3.16A, lanes 3-5). The AR phospho-Ser-578 specific antibody also recognized 
the faster migrating 21 kDa form of wild-type AR-(507-919) but not the S578A mutant 
(Figure 3.16B, upper panel, lanes 2-5), whereas both forms were detected using the AR52 
antibody (Fig. 3.16B, lower panel). Treatment with λ-phosphatase reduced the reactivity 
of the phospho-Ser-578 antibody reactivity with wild-type AR-(507-919) (data not 
shown).  
These results suggest that the EGF-dependent increase in AR transcriptional 
activity and CWR-R1 cell growth are associated with MAP kinase dependent 
phosphorylation at AR Ser-515 in the NH2-terminal region, and modulation by 
phosphorylation at Ser-578 in the DNA binding domain.  
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EFFECTS ON AR TRANSCRIPTIONAL ACTIVITY OF PHOSPHORYLATION MUTANTS IN 
CWR-R1 AND ISHIKAWA CELLS          
 
  We investigated further the link between EGF dependent AR phosphorylation and 
increased AR transcriptional activity using full-length wild-type AR and serine to alanine 
mutants expressed with a PSA-Enh-Luc reporter in CWR-R1 cells. AR transcriptional 
activity increased ~3 fold in response to EGF in the absence and presence of DHT 
(Figure 3.17A, upper panel). A similar response was seen with AR-S650A, which has a 
mutation in the previously reported Ser-650 phosphorylation site in the hinge region of 
AR (28, 29). AR-S515A transcriptional activity increased in response to EGF and DHT, 
but overall activity was less than wild-type. In contrast, EGF did not increase the 
transcriptional activity of AR-S578A in the absence or presence of DHT, or when the 
S578A mutation was combined with the S515A or S650A mutation. When assayed by 
immunoblot (Figure 3.17A, lower panel), expression of AR-S578A and AR-S515A was 
similar to wild-type AR, as was androgen dependent AR stabilization that results from 
the AR N/C inteaction (4, 23).  
  The weaker transcriptional activity of the AR-S578A DNA binding domain 
mutant did not result from loss of DNA binding. This was evident from AR-(1-660)-
S578A, a constitutively active AR NH2-terminal and DNA binding domain fragment that 
retained the transcriptional activity of wild-type AR-(1-660) using the PSA-Enh-Luc 
reporter (Figure 3.17B, upper panel). However, similar to results with full-length AR-
S578A shown in Figure 3.17A, transcriptional activity of AR-(1-660)-S578A did not 
increase in response to EGF, even though expression levels of AR-(1-660)-S578A were 
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similar to wild-type AR-(1-660) (Figure 3.17B, lower panel). AR-(1-660)-S578A also 
constitutively activated the MMTV-Luc reporter, even though full-length AR-S578A was 
inactive with this promoter (data not shown).  
To further establish the requirement for Ser-578 in the EGF dependent increase in 
AR transcriptional activity, we performed transcription assays in human endometrial 
cancer Ishikawa cells using the PSA-Enh-Luc reporter. In the presence of increasing 
concentrations of DHT, AR-S578A transcriptional activity was similar to wild-type AR. 
This differed from CWR-R1 cells where AR-S578A transcriptional activity was less than 
wild-type AR. However, in agreement with results with the CWR-R1 cell line, the EGF 
dependent increase in wild-type AR transcriptional activity seen in the presence of DHT 
was diminished by the AR S578A mutation in Ishikawa cells (Figure 3.18).  
  The results suggest that phosphorylation at AR Ser-578 is required for the AR 
transcriptional response to EGF.  
PKC-MEDIATED PHOSPHORYLATION WITHIN THE AR DBD AND ITS ROLE IN EGF-
DEPENDENT CWR-R1 PROSTATE CANCER CELL GROWTH 
 
  Ser-578 is a predicted consensus phosphorylation site for PKC, a kinase that acts 
downstream of EGF signaling (30). We performed in vitro kinase assays using the PKC 
catalytic subunit with wild-type GST-AR-(1-660) and S578A mutant. PKC 
phosphorylation of GST-AR-(1-660) was reduced 30–35% by the S578A mutation when 
equivalent amounts of protein were assayed by immunoblot (Figure 3.19A, lanes 1 and 
2), where Histone H1 served as a PKC substrate control (Figure 3.19A, lane 3). When 
averaged over multiple experiments, the S578A mutation decreased GST-AR-(1-660) 
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phosphorylation by ~50% (Figure 3.19B). Furthermore, transient transfection of AR1-
660 in CWR-R1 cells in the presence or absence of Calphostin, a PKC inhibitor, 
demonstrated that PKC plays a role in the constitutive activation of the AR mutant 
(Figure 3.19C). There was residual EGF-induced transcriptional activation suggesting 
PKC-mediated effects are regulated through multiple AR sites.  The EGF dependent 
increase in CWR-R1 cell growth (Figure 3.19D) was reduced in the presence of 50 nM 
Calphostin.   
These results support the concept that EGF signaling through PKC 
phosphorylation at AR Ser-578 increases AR transcriptional activity and AR mediated 
CWR-R1 cell growth.  
 
AR SER-578 PHOSPHORYLATION INFLUENCES NUCLEAR-CYTOPLASMIC SHUTTLING 
 
The effect of Ser-578 phosphorylation on AR subcellular localization was 
investigated using Flag-AR-(507-660) and the S578A mutant. Immunostaining showed 
that wild-type Flag-AR-(507-660) was distributed between the nucleus and cytoplasm of 
transfected COS cells, indicative of nuclear-cytoplasmic shuttling (Figure 3.20A, left 
panel). The phosphomimetic Flag-AR-(507-660)-S578D was distributed similarly 
between the nucleus and cytoplasm (data not shown). In contrast, immunostaining of 
Flag-AR-(507-660)-S578A was exclusively nuclear (Figure 3.20A, right panel).  
The influence of Ser-578 phosphorylation on AR compartmentalization was also 
investigated by comparing nuclear and cytoplasmic extracts of cells expressing Flag-AR-
(507-660) and the S578A mutant before and after treatment with EGF. In agreement with 
the immunostaining results, wild-type Flag-AR-(507-660) was in both the nuclear and 
 75 
 76 
cytoplasmic fractions, where the slower migrating Ser-515 phosphorylated form was 
prominent only in the nuclear fraction in response to EGF (Figure 3.20B, lanes 2, 3, 7 and 
8). Flag-AR-(507-660)-S515A lacked the slower migrating form (see Figure 3.14) and 
distributed in both nuclear and cytoplasmic extracts similar to wild-type (data not 
shown). However, in agreement with the immunostaining results, Flag-AR-(507-660)-
S578A was predominant only in nuclear extracts, with a greater proportion of the 
phosphorylated Ser-515 form (Figure 3.20B, lanes 4, 5, 9 and 10). Parallel 
immunoblotting of nuclear laminin-B1 and cytoplasmic α-tubulin substantiated the 
subcellular fractionation procedure. Cell extracts contained similar amounts of wild-type 
and mutant Flag-AR-(507-660) (data not shown), suggesting that the smaller amount of 
the S578A mutant in the cytoplasmic fraction did not result from degradation.  
These results suggest that EGF dependent phosphorylation at AR Ser-578 limits 
nuclear phosphorylation at Ser-515 and modulates AR nuclear-cytoplasmic shuttling. 
AR SER-578 PHOSPHORYLATION MODULATES THE AR INTERACTION WITH KU-70/80 
INDEPENDENT OF AR BINDING TO DNA 
 
The Ku-70/80 regulatory subunits of DNA-PK were shown previously to interact 
with the progesterone receptor DNA binding domain (31), which shares sequence 
similarity to the AR DNA binding domain (32). Ku-70/80 subunits were also implicated 
in AR transcriptional recycling (33). To address the influence of Ser-578 phosphorylation 
on the AR interaction with Ku-70/80, we performed coimmunoprecipitation studies in 
COS cells using full-length wild-type Flag-AR, the S578A mutant and endogenous Ku-
70/80. We found that Ku-70 and Ku-80 coimmunoprecipitated with Flag-AR-S578A, but 
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only weakly with wild-type AR (Figure 3.21A, upper two panels). In similar experiments 
using Flag-AR-(507-660), we found that the S578A mutant interacted with endogenous 
Ku-70 and Ku-80 to a greater extent than wild-type Flag-AR-(507-660) in both COS 
(Figure 3.21B) and CWR-R1 cells (Figure 3.21C). Also, as seen with full-length Flag-
tagged AR, the interaction between wild-type Flag-AR-(507-660) and Ku-70/80 
increased in the response to EGF in both cell lines. A DNA binding mutant, Flag-AR-
(507-919)-C576A, interacted with Ku-70/80 indicating the interaction is not dependent 
on AR/DNA binding (Figure 3.22).  
These results suggest that EGF dependent phosphorylation at AR Ser-578 
modulates phosphorylation at Ser-515 and regulates AR interaction with the Ku-70/80 
regulatory subunits of DNA-PK. 
INHIBITION OF AR-MEDIATED MMTV-LUC TRANSCRIPTION BY A NEGATIVE 
REGULATORY ELEMENT-1 (NRE-1)  
 
Transient transfection in Ishikawa cells revealed AR-S578A did not activate 
MMTV-Luc (Figure 3.23) but it does transactivate PSA-Enh-Luc which lacks NRE-1. 
Ku-70/80 repressed GR transactivation through high affinity, sequence specific binding 
to double stranded NRE1 at -394 to -381 in the MMTV long terminal repeat (141,156). 
Repression of GR transactivation of the MMTV promoter correlated with recruitment of 
Ku-70/80 to NRE1 (141,157). To determine whether AR-mediated activation of MMTV 
–Luc is regulated by NRE-1, two MMTV-LTR deletion mutants were tested. Deletion 
mutant 1 lacked a sequence of NRE-1 (NRE∆-381 – -394) (MMTV–∆NRE1-Luc) that is 
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conserved among other NRE-like sequences (141). Deletion mutant 2 lacked the NRE-1 
region (NRE∆-421-364) (MMTV–∆NRE2-Luc). CWR-R1 (Figure 3.24A) and Ishikawa 
(Figure 3.24B) cells were transfected with wild-type-MMTV-Luc, MMTV–∆NRE1-Luc 
or MMTV–∆NRE2-Luc reporter gene. In the absence of NRE-1 (-421– -364) there was a 
~2 fold increase in the androgen-dependent transcriptional activation suggesting that 
NRE-1 functions as a regulatory element in MMTV-promoter transactivation by AR.  
To test the hypothesis that phosphorylation at AR-Ser-578 decreases the 
interaction with Ku-70/80 to inhibit NRE-1-mediated down-regulation of MMTV 
transcription, pCMV-AR-S578A was cotransfected with MMTV-Luc or MMTV–
∆NRE2-Luc in CWR-R1 cells. Transcriptional activation of MMTV-Luc by AR-S578A 
was increased in MMTV–∆NRE2-Luc. However, overall transcriptional activity by AR-
578A was ~10-fold lower than wild-type AR, indicating that Ku70/80-mediated 
regulation is not sufficient to impair MMTV-Luc transcriptional activation by AR-
S578A.  
To determine whether NRE-1-mediated inhibition of MMTV activation by AR is 
modulated by Ku-70/80, XR-V15B cells were transfected with pCMV-AR and MMTV-
Luc or MMTV–∆NRE2-Luc (Figure 3.25). The results indicate that in Ku-deficient cells, 
deletion of NRE-1 increases AR activation of MMTV-Luc transcriptional activation by 
AR. Reconstituting AR by cotransfecting AR and Ku80 resulted in partial inhibition of 
MMTV transcription. This suggests that in the context of androgen signaling, inhibition 
of MMTV transcription has both Ku-70/80 dependent and independent pathways. 
Additional studies are required to determine the mechanisms of MMTV regulation by 
NRE1 in AR signaling pathways.  
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DISCUSSION 
 
 
EGF AND TIF2 IN CASTRATION- RECURRENT PROSTATE CANCER 
 
Castration-recurrent prostate cancer expresses levels of AR similar to those found 
in androgen-stimulated prostate cancer and benign prostate. This observation suggests 
that the AR is important for growth regulation in castration-recurrent prostate cancer. 
Findings suggest prostate cancer that recurs during androgen deprivation therapy remains 
androgen dependent. Recent reports have demonstrated testosterone levels in castration-
recurrent prostate cancer are sufficient to activate AR and up-regulate androgen response 
genes (76).  Our studies have elucidated mechanisms by which growth factors increase 
AR activity in the presence of low levels of androgen (79,80).  
EGF increased androgen-dependent AR transactivation in association with 
increased levels of TIF2 in the CWR-R1 cell line suggests p160 coactivators play a role 
in progression of prostate cancer. To investigate the function of EGF on TIF2 mediated 
increase of AR transcriptional activation in CWR-R1 cells, we explored the possibility of 
TIF2 mRNA up regulation by EGF. Our results demonstrated similar TIF2 mRNA levels 
in the absence and presence of EGF suggesting EGF does not play a regulatory role at the 
level of TIF2 transcription. Reducing TIF2/GRIP1 levels in CWR-R1 cells using 
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inhibitory RNAs resulted in a decreased AR transcriptional response to DHT and EGF. 
The data provide evidence for a direct link between AR transcriptional activity in 
recurrent prostate cancer, EGF signaling, and increased p160 coactivator levels. Data 
from our studies indicated increased AR transcriptional activity occurs in response to 
EGF in part from an increase in the androgen-dependent association between AR and 
TIF2 and that the EGF-induced increase in AR transactivation was linked to MAPK-
mediated phosphorylation of TIF2 (79). Future studies addressing the clinical 
implications of EGFR and MAP kinase inhibitors on TIF2 expression and AR activity 
after androgen deprivation therapy are necessary to evaluate the biological significance of 
these pathways in castration recurrent prostate cancer. Xenograft studies in the absence 
and presence of androgen, EGFR and MAP kinase inhibitors would elucidate the 
dependence of CWR-R1 cell tumorogenic potential on EGF-mediated phosphorylation of 
TIF2.   
 
EGF AND THE AR N/C INTERACTION 
 
Transient expression of TIF2 in the presence of DHT and EGF had a stabilizing 
effect on AR FXXAA/AXXAA, an AR with mutations in the NH2-terminal 23FQNLF27 
and 433WHTLF437 sequences that are required for the androgen-induced AR N/C 
interaction (40,47,48,150,158). Mutations that cause loss of the N/C interaction allow 
greater accessibility of AF2 in the ligand binding domain to activation by p160 
coactivators such as TIF2 (48,150). Surprisingly, whereas loss of the N/C interaction 
reduced AR transactivation of the PSA promoter in other cell lines (47), this mutant was 
as effective as wild-type AR when assayed in the CWR-R1 cell line, supporting the 
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notion that higher levels of TIF2 compensate for loss of the AR N/C interaction. DHT is 
thought to be the main modulator of AR dimerization but little is known about the effects 
of growth factors in this key regulatory event. Mammalian two hybrid interaction assays 
have been used extensively to study the AR N/C interaction and to determine the effects 
of EGF on AR interaction with TIF2 (40). In data not shown here, interaction of GAL4-
AR1-503 with the AR-VP16 fusion vector increased in the presence of DHT and EGF as 
compared to DHT alone as demonstrated by the transcriptional activation of the 
5XGAL4-Luc reporter. This suggests EGF plays a role in the AR N/C interaction and 
may modulate AR activity through mechanisms involving receptor dimerization. The 
EGF-induced increase in DHT-mediated N/C interaction was abrogated by VP16-AR-1-
507-S308A indicating   a link between EGF-mediated serine phoshorylation in the AR N-
terminal domain and AR dimer formation.  Future studies addressing AR-Ser-308 
phosphorylation are important to determine the role of post-translational modifications in 
AR dimerization and the mechanism by which EGF drives AR function in castration 
recurrent prostate cancer. These studies could provide evidence to support the design of 
therapies targeting EGF signaling, the AR N/C interaction and kinases involved in 
promoting recurrence in the presence of low levels of androgen.  
 
EGF REGULATION OF AR TRANSCRIPTIONAL ACTIVITY 
 
EGF signaling has been indirectly linked to increased AR transcriptional activity 
through the post-translational modification of AR coregulatory proteins. EGF increases 
phosphorylation and multiple mono-ubiquitinylation of MAGE-11 of the melanoma 
antigen gene family (46). These changes stabilize the coregulator interaction with AR to 
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increase AR transcriptional activity. In our studies we provide evidence that EGF 
increases AR transcriptional activity through the coordinate phosphorylation of serine 
residues in the AR NH2-terminal and DNA binding domains.  
We have shown that EGF increases CWR-R1 prostate cancer cell growth in an 
AR dependent manner in the absence and presence of androgen. EGF acts synergistically 
with DHT to stimulate AR transcriptional activity and cell growth. EGF-dependent 
CWR-R1 prostate cancer cell proliferation was greatest in the presence of AR and DHT 
and was reduced by an inhibitor of PKC. One interpretation suggests that AR signaling in 
the absence and presence of DHT establishes a basal proliferation rate which is enhanced 
by EGF through mechanisms that include AR but are also independent of AR. EGF 
dependent AR activation in the absence and presence of androgen is mediated by PKC 
dependent phosphorylation at Ser-578 in the AR DNA binding domain and by MAP 
kinase dependent phosphorylation at Ser-515 in the AR NH2-terminal region. The 
downstream functional effects of AR phosphorylation at these sites alter AR nuclear-
cytoplasmic shuttling through interactions with Ku-70/80.  
 
EGF-DEPENDENT AR PHOSPHORYLATION 
 
Earlier mutagenesis studies demonstrated AR phosphorylation at Ser-81 and Ser-
94 in the NH2-terminal region, and at Ser-650 in the hinge region between the DNA and 
ligand binding domains (88). AR Ser-81 was suggested to be a substrate for the HER2 
regulated kinase pathway (99) and AR phosphorylation at Ser-650 was linked to stress 
kinase modulation of AR transcriptional activity (159). However, mutations at these sites 
have relatively little effect on AR transcriptional activity (88,94). Mass spectrometry 
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confirmed AR phosphorylation at Ser-81, 94 and 650, and identified Ser-16, 256, 308 and 
424 as phosphorylation sites in the AR NH2-terminal region (85). AR NH2-terminal Ser-
213 was phosphorylated in nonproliferating prostate epithelial cells (89), and Akt 
mediated phosphorylation at AR Ser-213 and Ser-791 was linked to anti-apoptotic and 
proliferative effects in prostate cancer cells (86,160). However, the synergistic effects of 
Akt and AR on neoplastic proliferation of murine prostatic epithelium were independent 
of phosphorylation at these sites (161). More recently, prostate cancer growth was linked 
to Src and Ack1 mediated phosphorylation of AR tyrosine residues 267 and 363 in the 
AR NH2-terminal region (95,162).  
Our current studies focused on the AR DNA binding domain and flanking NH2-
terminal and hinge regions and confirmed that a mutation at Ser-650 has relatively little 
effect on AR transcriptional activity (88,94). We also found that mutations at other 
previously reported phosphorylation sites in the region, including a recently reported Src 
dependent tyrosine phosphorylation site Tyr-534 in the AR NH2-terminal region close to 
the DNA binding domain (95), did not diminish AR transcriptional activity in CWR-R1 
cells in response to DHT with or without EGF. The relative lack of functional effects of 
mutations at most of the previously reported AR phosphorylation sites left unanswered 
the question of the significance of AR phosphorylation, particularly in prostate cancer 
cells where growth factor and mitogen signaling are increased.  
Our studies indicate direct effects of EGF signaling on AR transcriptional activity 
through Ser-515 in the NH2-terminal region and Ser-578 in the DNA binding domain. 
MAP kinase phosphorylation site Ser-515 is positioned near the DNA binding domain 
(Figure 4.1A) carboxyl-terminal to AF1 transactivation domain residues 142-337 
required for androgen dependent AR transcriptional activity (37,163). AR Ser-515 is 
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closer to tau-5 residues 360-485 (164), a transcriptional activation region whose activity 
is apparent in the AR NH2-terminal and DNA binding domain fragment that lacks the 
ligand binding domain (37,163).  
MAP kinase signaling was previously implicated in androgen dependent AR 
transcriptional activity (79,80,165). In vitro MAP kinase assays suggested 
phosphorylation of AR-36-643, an AR NH2-terminal and DNA binding domain fragment, 
in response to HER2/neu signaling (107). Although an AR S515A mutation reduced the 
signaling effects of HER2/neu, additional evidence for phosphorylation at this site was 
not reported. Here we show that EGF signaling slowed the gel electrophoretic migration 
of an AR NH2-terminal–DNA binding domain–hinge region fragment, an effect that was 
eliminated by treatment with λ-phosphatase. The EGF dependent increase in AR 
transcriptional activity was linked to phosphorylation at Ser-515 and Ser-578. MAP 
kinase consensus site mutation S515A reduced AR transcriptional activity slightly, but 
did not eliminate the AR transcriptional response to EGF in the absence and presence of 
androgen. Inhibition of Ser-578 phosphorylation by an S578A mutation increased 
phosphorylation at Ser-515, which provided evidence that AR phosphorylation at Ser-515 
is linked to phosphorylation at Ser-578.  
Indeed, EGF-dependent phosphorylation at AR Ser-578 appears to be required for 
EGF stimulation of AR transcriptional activity. Ser-578 is positioned in the first zinc 
module of the AR DNA binding domain (Figure 4.1B) within the P-box. Response 
element DNA binding specificity distinguished by the glucocorticoid receptor (GR) and 
estrogen receptor is associated with three P-box residues, GSxxV (116,166). Human AR 
P-box 577GSCKV581 contains Ser-578 and is common to GR and the progesterone and 
mineralocorticoid receptors, each of which recognizes the GGTACAnnnTGTTCT 
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consensus response element (167-169). P-box squence within this subfamily 
distinguishes TGTTCT half-site sequence from TGACCT estrogen response element 
consensus sequence (166). Within the AR receptor subgroup, DNA response element 
binding specificity was attributed to residues in the second zinc module and the carboxyl-
terminal extension in the hinge region (169,170).  
Crystal structures of the AR DNA binding domain–androgen response element 
DNA complex indicate that human AR Ser-578 lies within the first alpha helix that 
directly contacts the major groove of the DNA (Figure 4.1 C) (171). Human AR Ser-578 
corresponds to human GR Ser-440. When GR Ser-440 was changed to glycine to mimic 
Gly-204 in human ER or to alanine, GR DNA binding specificity was reduced. Based on 
these studies, the AR Ser-578 hydroxyl group is predicted to modulate DNA binding 
specificity through a hydrogen bond network extending to Arg-608 in the second zinc 
module loop containing AR D-box 596ASRND600 (Figure 4.1B) (172). Unlike the 
common P-box sequence shared by AR, GR, progesterone and mineralocorticoid 
receptors, the AR D-box, thought to be involved in receptor dimerization and half site 
spacing recognition, differs from the AGRND D-box common to other members of this 
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subgroup of steroid receptors (115,116). AR Arg-608 corresponds to Arg-470 in human 
GR, for which a lysine substitution was predicted to alter DNA binding specificity by 
changing the hydrogen bonding pattern (172). The importance of AR Arg-608, which 
contacts the DNA phosphate backbone and is conserved in the steroid receptor family, is 
supported by the naturally occurring R608K mutation that causes partial androgen 
insensitivity (www.mcgill.ca/androgendb/).  
A naturally occurring AR S578T mutation also causes grade 5 partial androgen 
insensitivity, where complete androgen insensitivity (grade 6/7) is associated with an 
external female phenotype in a genetic male (173,174). The S578T mutation 
demonstrates the importance of Ser-578 in AR function in vivo. The partial response of 
recombinant AR-S578T to elevated androgen levels in a COS cell transcriptional assay 
(174) indicates some retention of DNA binding activity. The extent of phosphorylation at 
residue 578 may be diminished by threonine at this position and phospho-Ser-578 or 
phospho-Thr-578 might alter AR interaction with DNA (Figure 4.1C) or associated 
proteins such as Ku-70/80. Rapid release and rebinding of steroid receptors to DNA in a 
dynamic hit-and-run model has revealed the transient nature of steroid receptor DNA 
binding required for activation of transcription (175,176). Similar transient interactions 
were reported for AR binding to androgen response element DNA (177). EGF dependent 
phosphorylation at AR Ser-578 may regulate AR association and dissociation from DNA 
and the magnitude of the transcriptional response.  
We have provided evidence for PKC phosphorylation at AR Ser-578. Our results 
support previous evidence that phosphorylation by PKC in the DNA binding domain 
modulates nuclear receptor localization. PKC was shown to phosphorylate highly 
conserved Ser-78 between the two zinc modules in the DNA binding domain of 
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hepatocyte nuclear factor-4α (HNF-4α), and at a corresponding position in retinoic acid 
receptor-α, retinoid X receptor-α and thyroid hormone receptor-α (60). HNF-4α Ser-78 is 
conserved through most of the nuclear receptor superfamily, including Ser-212 in human 
estrogen receptor-α. However, the corresponding residue in the AR subgroup of steroid 
receptors is alanine and is Ala-586 in human AR. PKC phosphorylation at Ser-78 in the 
DNA binding domain of HNF-4α and other nuclear receptors regulates nuclear 
localization (178). HNF-4α-S78A bound DNA, but the S78D phosphomimetic did not. 
The AR phosphomimetic S578D retained greater transcriptional activity than AR-S578A, 
but less than wild-type AR (data not shown), and like wild-type AR, the S578D mutant 
was distributed in both the cytoplasm and nucleus. AR-S578D might be expected to bind 
less Ku-70/80, which could interfere with the dynamic model of steroid receptor binding 
to DNA.  
Phosphorylation in the DNA binding domain of different nuclear receptors has 
been involved with changes in the regulation of gene transcription. Black et al. (179) 
demonstrated that mutations in the AR DBD ∆F582 and F582Y and the export mutant 
F582,573A displayed androgen-dependent arrest in foci were steroid receptor coactivator 
glucocorticoid receptor-interacting protein (GRIP)-1 is highly expressed. The data 
suggest that wild-type AR induces rapid, agonist dependent dissociation of GRIP-1 from 
subnuclear foci, which may facilitate interactions between nuclear receptors and 
coactivators before transcription. The AR-C619Y mutant, which alters a cysteine that 
coordinates zinc in the AR DNA binding domain, was transcriptionally inactive and 
unable to bind DNA and localized abnormally in nuclear aggregates that also contain 
SRC-1, suggesting that this mutant may alter cellular physiology through sequestration of 
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critical proteins (180). This data agrees with our observation that modifications on the 
AR DBD regulate AR localization and interactions with coregulators.  
Studies indicate there is convergence between the PKC and androgen-mediated 
pathways. Analysis of the PKC δ promoter revealed a putative androgen responsive 
element (ARE) located 4.7 kb upstream from the transcription start site and luciferase 
reporter assays show that this element is responsive to androgens (93). Crosstalk between 
PKC and other kinases was demonstrated by studies using phorbol 12-myristate 13-
acetate which activates p38 MAPK in LNCaP cells the induction of apoptosis (181). Its 
been shown that the basal level of PKCε protein is elevated in recurrent CWR22 
xenograft tumors and subconfluent cultures of androgen independent prostate cancer cell 
lines (DU145 and PC-3), relative to androgen-sensitive prostate cancer cell lines 
(CWR22 tumors and LNCaP cells) (182).  
The results raise the possibility that phosphorylation by PKC at conserved serine 
residues in the first zinc module of the DNA binding domain regulates DNA binding for 
the entire nuclear receptor family. Phosphorylation within the DNA binding domain may 
be a common regulatory mechanism that controls nuclear-cytoplasmic shuttling and DNA 
binding required for differential gene regulation. 
 
AR NUCLEAR-CYTOPLASMIC SHUTTLING AND DNA BINDING SPECIFICITY 
 
EGF-dependent AR transcriptional activity mediated by PKC-dependent 
phosphorylation at AR Ser-578 is linked to AR nuclear-cytoplasmic shuttling. Based on 
results with an AR NH2-terminal, DNA binding and hinge region fragment, where the 
S578A mutant was exclusively nuclear, EGF dependent AR phosphorylation at Ser-515 
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and Ser-578 modulates AR nuclear retention. In addition, AR coimmunoprecipiates with 
Ku-70/80, a DNA binding protein complex that regulates DNA-PK activity and other 
transcription factors (183). The greater nuclear retention of AR-(507-660)-S578A 
compared to wild-type was associated with increased interaction with Ku-70/80. PKC 
mediated AR phosphorylation at Ser-578 appears to regulate the AR interaction with Ku-
70/80 and modulate AR nuclear-cytoplasmic shuttling and DNA binding. Our studies are 
in agreement with previous evidence that steroid receptor phosphorylation is linked to 
nuclear-cytoplasmic shuttling (184).  
In agreement with evidence that AR-S578A interacts to a greater extent with Ku-
70/80, full-length AR-S578A did not activate MMTV-Luc in Ishikawa cells (data not 
shown), even though AR-S578A transcriptional activity was similar to wild-type in 
Ishikawa cells using the PSA-Enh-Luc reporter which lacks a negative response element 
(NRE) sequence present in the MMTV promoter-enhancer. Ku-80 represses GR 
transactivation through high affinity, sequence specific binding to double stranded NRE1 
at -394 to -381 in the MMTV long terminal repeat (141,156). Repression of GR 
transactivation of the MMTV promoter correlated with recruitment of Ku-70/80 to NRE1 
(141,142,157).  
Loss of AR-S578A transactivation of MMTV-Luc did not result from inhibition 
of AR binding to DNA. In the context of the AR NH2-terminal and DNA binding domain 
constitutively active fragment, AR-S578A retains wild-type activity with MMTV-Luc 
(data not shown). This is consistent with a previous study suggesting that Ku-70/80 
interacts preferentially with the AR ligand binding domain and provides further evidence 
that the effect of the S578A mutation is to increase AR interaction with Ku-70/80. A 
study demonstrated nuclear AR was transcriptionally active on prostate-specific antigen 
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and MMTV promoters driving reporter genes. AR forced to the cytoplasm was largely 
inactive on the prostate-specific antigen promoter, but AR was active on the mouse 
mammary tumor virus promoter and on two endogenous genes examined (185).  Our 
studies suggest that a stronger interaction between AR and Ku-70/80 is associated with 
loss of AR activation of MMTV. In addition, the results support the concept that EGF 
dependent phosphorylation at Ser-578 modulates AR transactivation through its 
interaction with Ku-70/80.  
EGF-dependent phosphorylation sites Ser-515 and Ser-578 in AR differ from the 
GR DNA-PK phosphorylation site that was linked to GR association with Ku-70/80. 
Human GR hinge region DNA-PK phosphorylation site Ser-508 implicated in GR 
nuclear retention (142,156,186) is positioned close to human GR nuclear targeting 
residues 479-498, and displaced in position by two residues to the corresponding human 
AR hinge residue Ser-650 near AR nuclear targeting residues 617-633 (158,187). We and 
others have shown that a mutation at Ser-650 has relatively little effect on AR 
transcriptional activity (88,94). However, human AR has a DNA-PK consensus 
phosphorylation site 656TQ657 in the hinge region and inhibition of DNA-PK was reported 
to reduce AR phosphorylation and nuclear export (136). Given that AR interacts with Ku-
70/80, an interaction that is enhanced by the S578A mutation, and that Ku-70/80 has 
additional functions independent of DNA-PK (157), Ku-70/80 may regulate AR 
independent of DNA-PK. Ku-70/80 is reported to have DNA helicase activity (188) 
which may more directly influence AR transcriptional activity. 
   
AR FUNCTION IN CASTRATION-RECURRENT PROSTATE CANCER 
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AR is an important transcriptional activator in castration-recurrent prostate cancer 
growth that follows a period of remission in response to androgen deprivation therapy. 
The AR gene is amplified in approximately one third of prostate cancers (189). AR 
somatic gene mutations in prostate cancer can increase AR transactivation by androgens 
and other ligands. However, although AR mutations are relatively common in established 
prostate cancer cell lines, they are infrequent in prostate cancer tissue specimens and 
cannot account for the high incidence of castration-recurrent prostate cancer growth after 
androgen deprivation therapy. AR somatic mutations in prostate cancer, such as AR-
H874Y in the CWR22 human prostate xenograft and the derived CWR-R1 prostate 
cancer cell line used in the present study (66,69), tend to increase AR sensitivity to ligand 
dependent transactivation through more efficient recruitment of SRC/p160 coactivators 
by AF2 in the ligand binding domain (52). In contrast, ligand-independent AR activation 
may be independent of AF2 in the ligand binding domain (190), mediated instead by 
growth factor and mitogen downstream signaling mechanisms (191). This is supported by 
the inability of flutamide to inhibit castration-recurrent prostate cancer cell growth (192). 
Chromatin studies support AR function in cell proliferation in castration-recurrent 
prostate cancer in the absence of androgen (193-197). Adeno-associated viral siRNA 
knockdown of AR diminished both DHT and EGF stimulated CWR-R1 prostate cancer 
cell growth. However, residual levels of AR in the AR-siRNA-scAAV treated cells 
appear to be sufficient to mediate prostate cancer cell growth in response to the 
synergistic effects of DHT and EGF, a finding relevant to clinical prostate cancer since 
androgens are present in castration-recurrent prostate cancer tissue (75). In addition, EGF 
was shown to induce site specific phosphorylation and mono-ubiquitinylation of AR 
coregulator MAGE-11 required to interact with AR and increase transcriptional activity 
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in the absence and presence of androgen (198). Thus, growth factor and mitogen 
signaling through multiple mechanisms that involve AR may account for the relapse of 
prostate cancer growth.  
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FUTURE PERSPECTIVES 
 
 
PKC AND PROSTATE CANCER 
 
We explored the role of PKC on AR DBD phosphorylation utilizing the catalytic 
subunit of PKC, which is conserved between all isoforms. We demonstrated that PKC 
phosphorylates AR at Ser-578 to possibly allow transient nuclear localization of and 
interaction with coregulators Ku-70/80 from the DNA-PK trimeric complex. Our data 
indicates PKC-mediated phosphorylation may contribute to EGF activation of AR in 
androgen independent environments by promoting optimal nuclear/cytoplasmic 
trafficking and dissociation from nuclear coregulators.  
PKCα is necessary for EGFR signaling to ERK1/2 activation induced by phorbol 
esters in androgen-independent human prostate cancer PC-3 cells (199). However, among 
the PKC isozymes present in human prostatic epithelial cells, PKCε is implicated in 
counterbalancing the influence of PKCα and PKCδ by favoring a program that results in 
the malignant progression of prostate cancer (182). However, there is little clinical 
evidence at present to support a role for PKC in the development of castration recurrent 
prostate cancer and there is no clinical data to date demonstrating improved therapeutic 
outcome in response to PKC inhibition. Studies addressing PKC isoform expression and 
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activity during prostate cancer progression are required to determine if the PKC pathway 
a suitable therapeutic target for castration recurrent prostate cancer.  
 
RECURRENT PROSTATE CANCER AND EGF-MEDIATED SIGNALING 
 
Analyses have been performed by others to determine how nucleocytoplasmic 
shuttling contributes to the function of full-length AR utilizing heterokaryon assays in 
COS cells (185).  It is yet to be determined whether EGF-dependent phosphorylation of 
AR-Ser-578 by PKC regulates full-length AR nuclear export.  We examined the role of 
AR-Ser-578 phosphorylation by studying cellular localization of Flag-AR-(507-660) 5 h 
after EGF treatment. A more detailed look analyzing a larger range of EGF treatment 
time-points and concentrations as well as implementing the heterokaryon assay approach 
would help determine if the status of Ser-578 influences full-length AR cellular 
localization. Further, cells transformed with wild-type AR and AR-Ser-578 may provide 
a direct link between EGF, AR, PKC and CWR-R1 cell proliferation.  Specifically, 
CWR-R1 cells where AR is inhibited could be reconstituted with knock-down resistant 
versions of the wild type AR or AR-S578A mutant. This requires the generation of a 
stable cell line by either selecting transformed clones or introducing AR-Ser-578 
expression via a lentiviral vector. Cell proliferation assays with these AR-rescue cells 
may provide a direct test of the importance of AR-Ser-578 phosphorylation for the EGF-
stimulation of cell proliferation. Furthermore, cells expressing AR-S578A could be used 
in vivo to test their tumorgenecity in nude mice xenografts to determine if 
phosphorylation at AR-Ser-578 inhibits castration recurrent cell growth in testicular 
androgen-depleted environments.  
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DNA-PK AND PROSTATE CANCER 
 
This study provided a functional link between Ku-70/80 and AR. It is yet to be 
determined clinically if Ku-70/80 expression, cellular localization and interaction with 
AR plays a role in prostate cancer cell growth. It has been suggested that down-regulation 
of Ku-70/80 promotes progression of urothelial carcinogenesis to a more malignant and 
aggressive clinical behavior, presumably as a result of an impaired capacity for DNA 
repair (200). Furthermore, Ku-70 siRNAs induced a decrease in the surviving fraction of 
gamma irradiated human cervical epithelioid (HeLa) cells and similar sensitizing effects 
were observed for etoposide, a topoisomerase II inhibitor (201). A study investigated the 
Ku70/80 DNA-binding activity in human breast and bladder normal tissue and tumor 
biopsies. The tumor tissues revealed the existence of two different patterns in Ku-70/80 
DNA-binding activity, overall correlated to the progression of the neoplastic disease. 
Breast and non-invasive bladder tumors showed a high nuclear DNA-binding activity. 
Conversely, all the corresponding normal tissues displayed a very low basal level of the 
DNA-binding activity.  There are no clinical studies that correlate Ku-70/80 expression 
or cellular localization to sensitization to chemotherapy in prostate cancer patients. 
Analogous studies in the prostate are required to determine if Ku-70/80 activity after 
androgen deprivation influences AR function in the absence of testicular androgens and if 
targeting Ku-70/80 during recurrence is an effective mechanism for sensitization to 
chemotherapy.  
 
CLINICAL IMPLICATIONS 
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A major goal of this study was to provide evidence for the role of AR in castration 
recurrent prostate cancer. We provided evidence that AR-Ser-578 mediates EGF-
dependent activation of AR and plays a role in the DHT and EGF-mediated effects of AR 
transcriptional activation of the PSA-Enh-Luc reporter in CWR-R1 cells. It is yet to be 
determined if phosphorylation status of AR-Ser-578 is clinically relevant during evasion 
of androgen deprivation therapy. Immunohistochemistry of benign prostate, androgen-
dependent, and recurrent prostate cancer with the newly developed phospho-AR-Ser-578 
antibody would provide insight to whether Ser-578 phosphorylation contributes to 
prostate cancer recurrence. This may be a challenging goal because the newly-generated 
phosphospecific antibody requires optimization for immunoblotting and immunostaining. 
However, it would be clinically relevant to determine if the phosphorylation status of 
AR-Ser-578 correlates to progression towards prostate cancer recurrence. Furthermore, 
the DNA-PK consuensus site on AR 656TQ657 was not analyzed in this study. Mutating 
this site and performing functional assays would be important to determine if DNA-PK 
phosphorylation plays a role in AR-mediated signaling in CWR-R1 cells.   
scAAV vectors have been shown to deliver hairpin siRNA into multidrug-
resistant human breast cancer cells and oral cancer cells (202). Furthermore, the 
feasibility of various scAAV serotypes as efficient gene delivery vehicles in human 
cancer cells was recently evaluated. Substantial transgene expression lasted over 30 days 
in various cancer cells lines following gene delivery, indicating that long-term gene 
expression can occur (203). Thus, there is evidence suggesting that scAAV vectors are 
suitable gene transfer tools potentially applicable to a wide variety of human cancer cells, 
independently driving persistent transgene expression. scAAV-ARsiRNA inhibits AR 
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expression in culture up to 5 days after infection. Optimization of delivery, uptake, and 
transduction efficiency in vivo of scAAV-ARsiRNA may elucidate if scAAV-mediated 
decrease of AR protein is a suitable tool for inhibiting castration-recurrent prostate cancer 
cell growth.  
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